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Abstract 
Childbearing age women are often prescribed teratogenic medication without pregnancy risk or 
contraceptive counseling.  With a 45% unintended pregnancy rate, women are at risk of 
unintentional teratogenic fetal exposure. The TARCC framework created by Shroff, McNeil, and 
Borrero (2017), is an acronym that providers can use while prescribing medication to reduce the 
risk of teratogenic exposure. Ultimately, the increase in TARCC usage could lead to decreased 
teratogen prescription, increased birth control use while on a teratogen, and reductions in birth 
defects and elective abortion. The purpose of the Doctor of Nursing Practice project was to 
increase primary care provider knowledge and use of the TARCC framework at two urban 
clinics in NC.  The project interventions consisted of provider education, TARCC reminder 
cards, weekly teratogen information emails, and TARCC checklists to use during patient visits. 
The outcomes of the project included an increase in provider self-reported competence in 
TARCC usage and an increased provider awareness of safe prescribing. Site A had an average of 
16% (SD=6.9%) use of the TARCC checklist over ten weeks. Overall, it was recommended to 
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Chapter One:  Overview of the Problem of Interest  
 In the United States, women of childbearing age are often prescribed teratogenic 
medication without a discussion of pregnancy risk or contraceptive counseling (Mody, Farala, 
Wu, Felix, & Chambers, 2015; Schwarz, Maselli, Norton, & Gonzales, 2005; Shroff, McNeil, & 
Borrero, 2017). Taken during pregnancy, teratogenic medication can cause fetal growth and 
development problems, including miscarriage. Considering high unintended pregnancy rates, a 
fetus may be exposed to teratogenic medication before prenatal care is initiated. In addition, 
North Carolina (NC) has restrictive abortion regulations, which may affect a woman’s ability to 
terminate a pregnancy exposed to teratogenic medication early in pregnancy. Therefore, 
teratogenic effects on an unplanned or unintended pregnancy must be reduced. A Doctor of 
Nursing Practice (DNP) Project was conducted in two urban NC primary care clinics to increase 
provider awareness of the TARCC framework developed by Shroff et al. (2017). TARCC stands 
for teratogen, alternative, risks, contraceptive counseling, and charting (Shroff et al., 2017).  Use 
of the framework leads to a decrease in teratogenic prescriptions to childbearing age women. It 
also increases contraceptive and pregnancy risk counseling for women taking teratogenic 
medication.  
Background Information  
 Healthcare providers often prescribe teratogenic medications to women of childbearing 
age. Based on the National Health and Nutrition Examination Survey results from 1999 to 2006, 
47% of childbearing age non-pregnant women were prescribed at least one medication in the past 
30 days (Tinker, Broussard, Frey & Gilboa, 2015). Over half of the women were prescribed 
more than two prescriptions (Tinker et al., 2015). Five of the top ten prescribed medications 
require cautious use during pregnancy or were contraindicated (Tinker et al., 2015). Also, 
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between 2005 and 2009, approximately 10.1 million emergency department visits by 
childbearing age women resulted in teratogenic medication administration or prescription (Goyal 
et al., 2015). Last, between 1998 and 2001, 11.1% of primary care visits for childbearing age 
women resulted in teratogenic medication prescriptions (Schwarz et al., 2005). Therefore, 
childbearing age women are often prescribed teratogenic medications in both primary and acute 
care, increasing the risk of fetal exposure. 
  Unplanned pregnancy can result in fetal exposure to teratogenic medication during early 
pregnancy. In 2011, 45% of US pregnancies, that resulted in live births, were unintended (Finer 
& Zolna, 2016). Moreover, women in the United States may start prenatal care later than the first 
trimester. For example, in 2017, only 77.3% of women started prenatal care during the first 
trimester (Martin, Hamilton, Osterman, Driscoll, & Drake, 2018). Therefore, women who were 
on teratogenic medication before pregnancy could have exposed their fetus during the first 
trimester. In NC, 3% of babies are born with moribund birth defects (National Birth Defects 
Prevention Network [NBDPN], 2010). Those babies born with moribund birth defects account 
for 20% of NC infant mortality (NBDPN, 2010). Some of these birth defects develop in first 
trimester secondary to in-utero teratogen exposure (NBDPN, 2010). The hospital costs related to 
birth defects amounts to $2.6 billion in NC (NBDPN, 2010). Therefore, healthcare providers 
have an ethical and financial duty to reduce fetal teratogen exposure when prescribing the 
medication. 
  Contraceptive and pregnancy risk counseling when teratogenic medications are 
prescribed is not standard of care. Category D and X medications were part of the original Food 
and Drug Administration (FDA) classification system (FDA, 2008). Category D medications 
have shown human fetal risk, however in certain situations the benefit of the drug may outweigh 
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the risk of the drug (FDA, 2008). Opposingly, category X medications have shown to have fetal 
risk and never have benefits that outweigh the risk during pregnancy (FDA, 2008). Category X 
medications are therefore always contraindicated during pregnancy (FDA, 2008). Mody et al. 
(2015) found that family practice providers failed to advise contraception to 46.3% of women 
prescribed a category D or X medication. Similarly, 71% of women on teratogenic medications 
were not on contraception even though reproductive life plans were completed (DiPietro Mager, 
Mills, & Snelling, 2018). The problem extends to the Veterans Association where women are 
often placed on category D or X medications for mental illness or chronic disease (Shroff et al., 
2017). Over two years, only 12% of veteran women on teratogenic medication received 
contraceptive counseling (Shroff et al., 2017). In addition, in emergency departments, between 
2005 and 2009, 45.6% of women prescribed a D or X medication failed to have a pregnancy test. 
This fact illustrates providers’ unawareness of teratogenic medication dangers for childbearing- 
age women (Goyal et al., 2015). Lastly, Schwarz et al. (2005) found that only 6% of primary 
care visits, in which a teratogenic medication was prescribed, had documented contraceptive 
counseling or prescriptions. Healthcare providers are ethically bound to do no harm. Therefore, it 
is their responsibility to provide education about pregnancy risk and contraceptive options when 
prescribing teratogenic medications to childbearing age women. 
Of unintended US pregnancies in 2011, 42% were electively aborted (Finer & Zolna, 2016). 
Out of 1,209 abortion patients, 13% reported that one reason for choosing abortion was possible 
birth defects from prescription medications (Finer, Frohwirth, Dauphinee, Singh, & Moore, 
2005). Abortion is a timely topic in light of changing and tightening state abortion regulations. 
Some states are decreasing the maximum gestational age at which an abortion is legal. The 
legislation may make it more difficult for women to have an abortion if they discover the 
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pregnancy after the first eight weeks. Therefore, fewer unintended pregnancies and abortions 
through effective contraceptive counseling benefit the community, social service system, and 
healthcare system. Contraceptive counseling when teratogenic medications are prescribed 
educates women about unintended pregnancy consequences of medication use. 
Significance of Clinical Problem  
 Contraceptive counseling when prescribing teratogenic medication to childbearing age 
women is not routinely done. Providers reported three barriers, (1) lack of time, (2) knowledge 
deficit of alternative medications, and (3) proper methods for contraceptive counseling (Shroff et 
al., 2017). At one NC primary care practice, providers stated during informal discussions that 
they had no methods to ensure contraceptive counseling accompanied teratogenic medication 
prescriptions (M. Fike, personal communication, June 27, 2019). Providers reported they did not 
regularly provide counseling about pregnancy risk, reliable contraception, or Plan B when 
prescribing teratogenic medications (V. Dalalau, personal communication, June 27, 2019) . They 
also observed they did not habitually think of alternatives to teratogenic medications for 
childbearing age women (M. Fike, personal communication, June 27, 2019). Last, providers 
reported that lack of reminders and education were key barriers (M. Fike, personal 
communication, June 27, 2019).  
 In addition, baseline data for Fall 2018 were gathered from both primary care clinic 
project sites A and B. This period was chosen because the DNP project was implemented in Fall 
2019. During that time, 2,865 women between the ages of 18 and 50 were seen at sites A and B. 
(D. Allen, personal communication, Jan 29, 2020). At site A, 33% of those women were taking a 
teratogenic medication in one of the teratogenic classes focused on in the DNP project (D. Allen, 
personal communication, Jan 29, 2020). At site B, 50% of women were taking a teratogen (D. 
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Allen, personal communication, Jan 29, 2020). In Fall 2018, a total of 301 teratogenic 
medications were prescribed to childbearing age women at both clinics (D. Allen, personal 
communication, June 27, 2019). Of the women on teratogenic medications who reported they 
were sexually active, between 55% and 60% were not on birth control at both clinics (D. Allen, 
personal communication, Jan 29, 2019). Therefore, over half of the women were at risk for fetal 
exposure to teratogens. There was significant room for improvement at both clinic sites to reduce 
teratogenic prescriptions and to increase contraceptive counseling for women on them.  
Contraceptive counseling when teratogenic medications are prescribed would reduce 
unintended pregnancies and fetal exposure to teratogenic medications. Subsequently, termination 
rates and birth defect rates would decrease with subsequent lower healthcare costs (NBDPN, 
2010). With the NC restrictions on abortion, preventing one need for abortion, i.e., probable birth 
defects, would benefit the community and the healthcare system. The project was in line with 
Healthy People 2020 goals of reducing the number of infants born with birth defects, reducing 
infant mortality, increasing intended pregnancies, and increasing preconception discussion with 
childbearing age women (United States Department of Health and Human Services [USDHHS], 
n.d.). The purpose of the DNP project was to increase primary care provider knowledge and use 
of the TARCC framework. TARCC is a decision tree framework that helps providers increase 
the percentage of women using contraception while on a teratogenic medication and reduce the 
number of teratogenic prescriptions (Shroff et al., 2017). It is an acronym that stands for 
teratogenic, alternative, risk counseling, contraceptive counseling, and charting (Shroff et al., 
2017). First, providers determine if the medication they are prescribing is teratogenic and 
whether there is a safe and appropriate alternative (Shroff et al., 2017). If not, providers should 
discuss pregnancy risk and provide contraceptive counseling (Shroff et al., 2017). Finally, 
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providers should chart that an alternative was chosen or that appropriate risk and contraceptive 
counseling was performed (Shroff et al., 2017).  
Question Guiding Inquiry (PICO)  
Will an education session for family practice providers about the components of the 
TARCC framework increase their use of the framework and ultimately decrease the risk of fetal 
exposure to teratogenic medication? 
Population. The DNP project population was all primary care providers at two urban NC 
family practice clinics, which are part of the same health system. There were 14 providers that 
were included in the education session; seven at each site. Five providers were family nurse 
practitioners (FNPs), eight were physicians, and one was a physician assistant (PA).  
Intervention. The providers attended an education session about the importance of 
contraceptive and pregnancy risk counseling for childbearing age patients on teratogenic 
medications. They were introduced to a framework developed by Shroff et al. (2017) called 
TARCC. TARCC is a mnemonic that providers can use when they prescribe medication (Shroff 
et al., 2017). Providers gained awareness of commonly prescribed teratogenic medications in 
primary care based on literature review and safer alternatives. The pregnancy lactation labeling 
rule was discussed to give providers a tool in assessing risks/benefits of medications and 
providing accurate pregnancy risk counseling to patients (FDA, 2014). The Center for Disease 
Control (CDC) Medical Edibility Criteria and materials from the Family Planning National 
Training Center (FPNTC) was used to ensure guidelines were being followed for effective 
contraceptive counseling (CDC, 2016; FPNTC, 2019). Last, providers were given access to an 
easy method of documenting that this counseling was done in the electronic health record.  
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Comparison. Prior to the project, providers at the project sites did not routinely switch to 
safer medications for childbearing age women or document contraceptive counseling with 
prescription of teratogenic medications. There was no systematic way to identify teratogens or 
ensure reduced risk of fetal exposure. Providers had never used the TARCC framework as a 
routine part of medication prescription. Therefore, the purpose of the project was to increase 
provider knowledge and use of the TARCC framework.  
Outcome(s). The primary outcomes were increases in provider knowledge, competency, 
and use of the TARCC framework. There was no national benchmark or baseline for TARCC 
use, therefore no specific goal was set for the project. As a consequence of increasing provider 
knowledge and use of the TARCC framework, two long term outcomes were evaluated. First, the 
percentage of sexually active childbearing age (18-50 years) women using contraception while 
on a teratogenic medication. Additionally, the percentage of childbearing age women taking a 
teratogenic medication at the two primary care sites. Again, there was no national benchmark for 
the outcomes, therefore the metrics were compared before and after the project without a specific 
outcome percentage.  
Summary  
 Healthcare providers have an ethical and financial incentive to decrease the likelihood 
that a fetus is exposed to teratogenic medication. In addition, providers have a mandate to 
educate women about teratogenic effects on pregnancy and effective methods of contraception 
while on those medications. With the high rates of unplanned pregnancy in the US, providers 
cannot rely on the patient’s desire to avoid pregnancy but must educate about contraception and 
prescribe as indicated. Providers reported barriers such as lack of time, knowledge about safer 
alternatives, and effective means of contraceptive counseling. To overcome the barriers, the DNP 
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student educated 14 primary care providers about TARCC. In addition, providers learned about 
commonly prescribed teratogenic medications, alternatives, and methods to perform and 
document contraceptive counseling. With project success, sustainability includes placing all or 
parts of the TARCC framework into the electronic health record (EHR) for provider use at all 
clinics in the health system.  
 The DNP Project outcome was to increase provider knowledge and use of the TARCC 
framework. As a result of this, two outcomes were assessed and compared to baseline data from 
Fall 2018. First, the percentage of women using birth control while on a teratogenic medication. 
Second, the percentage of women taking a teratogen. Long-term implications of the outcomes 
will be a reduction in fetal exposure to teratogens, reduction in birth defects, and reduction in the 
need for elective abortion. The project outcomes and long-term implications aligned with 
Healthy People 2020 goals to increase preconception discussion in primary care, reduce birth 
defects, reduce infant mortality, and increase the percent of intended pregnancies.  
Chapter Two:  Review of the Literature  
A review of the literature assessed the gap between contraceptive counseling when 
prescribing teratogenic medication and current practice. Evidence identified contraceptive 
counseling barriers that were addressed in the DNP project intervention. In addition, the project 
outcomes aligned with national goals, Triple Aim, and professional organizational 
recommendations. Evidence limitations were explored. Lastly, the advantages and disadvantages 
of the project intervention were discussed.  
Literature Appraisal Methodology  
Sampling strategies. The literature search used East Carolina University’s (ECU) 
Laupus Library One Search which searched all databases and journal subscriptions. Search terms 
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included “teratogen*,” “childbearing age women,” “contraception”, “prescription,” and 
“counseling” (see Appendix A for Literature Review Search Log). Limits for the search were 
sources published within the past five years, English language, scholarly and peer-reviewed, and 
excluded dissertations. 119 articles were reviewed of which nine were selected for the literature 
review.  
A manual search of those nine articles’ references was another sampling strategy used for 
the literature review. Nine additional documents were found, including five articles >5 years due 
to their citation in other articles. Authors of the older documents are prominent US researchers in 
contraceptive counseling for teratogenic prescriptions. Three documents were national goals, 
organizational recommendations, or regulations rather than journal articles. One article was 
located with the “cited by” tool in One Search. In summation, 19 articles were used in the 
literature review. 
Evaluation criteria. Articles were evaluated first by abstract. The abstract determined if 
the content directly related to the DNP project’s clinical question. For example, abstracts on the 
teratogenicity of specific drugs, managing medications and medical conditions during pregnancy, 
pregnancy planning in specific medical conditions, and Isotretinoin iPledge program were 
excluded.  
Next, the subject sample was compared to US childbearing age women. Articles with 
interventions and outcomes specific to foreign or indigenous populations were not generalizable 
to US populations. Thus, they were excluded. Similarly, articles with samples of pediatric 
patients were excluded because the DNP project will include adult patients aged 18 to 50. 
Sample size was also used to exclude studies. Case reports and case studies with small sample 
sizes were excluded. Also, studies with vague implementation descriptions, low clinical 
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significance, and an inadequate discussion of statistical methods were excluded. Last, article 
methods and results sections were evaluated for rigor. For example, if data were gathered via 
survey, the authors must have addressed attrition, response rates, and confounding factors.  
Based on the preceding evaluation of each study, a level of evidence was assigned to 
denote the type of research performed using Melnyk Levels of Evidence (Melnyk & Fineout-
Overholt, 2011). All levels were included in the literature review except for levels II and VII (see 
Appendix B for DNP Project Literature Matrix) (Melnyk & Fineout-Overholt, 2011). Ten of the 
19 documents were level VI evidence: descriptive and qualitative studies (Melnyk & Fineout-
Overholt, 2011). One was level I evidence due to its inclusion of guidelines for clinical practice. 
One was level III because it was a cluster-randomized study. Three studies were level IV: 
correlational and case-control study designs (Melnyk & Fineout-Overholt, 2011). Two were 
systematic reviews of qualitative studies, i.e., level V evidence (Melnyk & Fineout-Overholt, 
2011). Two documents were not assigned levels of evidence because one is a national regulation 
and the other lists national goals.  
Literature Review Findings  
The evidence were mostly descriptive and qualitative studies that evaluated frequency of 
teratogenic medication prescription and if patients received contraceptive counseling. There were 
no multi-site, randomized control trials on the DNP topic. Due to the nature of the topic, 
retrospective designs predominated. It would be unethical to willingly withhold contraceptive 
counseling to women on teratogenic medication. Therefore, studies reported retrospective data 
on women who received teratogenic medication and if contraceptive counseling accompanied the 
prescription. The studies used correlational designs to assess patient and provider factors that 
may have affected counseling. Also, provider and patient surveys were used to identify barriers 
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to counseling and perceptions of pregnancy risk and contraceptive counseling. In addition, the 
American College of Obstetricians and Gynecologists (ACOG), American College of Physicians 
(ACP), American Academy of Family Physicians (AAFP), American Society for Reproductive 
Medicine (ASRM), and the National Association of Nurse Practitioners in Women’s Health 
(NPWH) produced guidelines based on systematic reviews (ACOG & ASRM, 2019; Women's 
Preventive Services Initiative, 2016).  
The need for improvement. There was a gap between (1) contraceptive counseling as 
part of routine, well-woman primary care, and (2) state of practice. National organizations such 
as ACOG, AAFP, ACP, ASRM, and NPWH called for contraceptive counseling and 
preconception planning at all health promotion visits for childbearing age women (ACOG & 
ASRM, 2019; Women's Preventive Services Initiative, 2016). Consequently, medication 
reconciliation in primary care should include assessment of teratogenic medication and 
contraception to decrease unintended pregnancy while on the medication (Women's Preventive 
Services Initiative, 2016). Also, Healthy People 2020 had goals around decreasing birth defects 
and increasing intended pregnancies (USDHHS, n.d.).  
Despite these evidence-based guidelines, studies consistently illustrated less than 60% of 
women received pregnancy risk counseling or contraceptive counseling when prescribed a 
teratogenic medication (Bhakta, Bainbridge, & Borgelt, 2015; DiPietro Mager et al., 2018; Goyal 
et al., 2015; Schwarz et al., 2005; Schwarz et al., 2012; Schwarz et al., 2013; Schwarz, 
Postlethwaite, Hung, & Armstrong, 2007; Shroff et al., 2017; Quinzanos et al., 2015). 
Teratogenic medication was often prescribed by general and family practice providers in primary 
care, outpatient settings (Schwarz et al., 2005; Schwarz et al., 2013). This was likely due to the 
management of chronic disease in primary care with teratogenic medication. For example, 
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hypertension, anxiety, depression, hyperlipidemia, diabetes, heart disease, and arthritis are all 
commonly managed in primary care and have first line teratogenic medications (Callegari, Ma, 
& Schwarz, 2015; Holton et al, 2018; Mody et al., 2015; Schwarz et al, 2013). However, women 
with these conditions were less likely to discuss contraception planning with their provider than 
women without chronic conditions (Holton et al., 2018). It follows that women with chronic 
diseases were, therefore, more likely to have unintended pregnancies and higher rates of abortion 
(Horton et al., 2018). Unfortunately, when women had an unintended pregnancy while on a 
teratogenic medication, they experienced a miscarriage or chose an abortion (Bhakta et al., 
2015).  
Support for the intervention. Evidence supported the DNP intervention of provider 
education. Both general medicine faculty and residents expressed a desire to have more 
education about contraception counseling as part of their training and continuing education 
(Dirksen, Shulman, Teal, & Huebschmann, 2014). The project education intervention addressed 
barriers cited in the literature such as lack of education about alternatives to teratogenic 
medication, confidence in providing contraceptive counseling, and comfort in discussing 
pregnancy risks (Dirksen et al., 2014; Shroff et al., 2017). Another barrier to risk counseling was 
the original FDA pregnancy risk categories: A, B, C, D, and X. It was found that the categories 
lacked substantive information about risks and benefits, teratogenicity, and required 
contraception before or during treatment (FDA, 2014). As a result, the FDA issued a new 
pregnancy and lactation labeling rule in 2015 to combat these issues, which will be included in 
the provider education session (FDA, 2014).  
 Contraceptive counseling is supported in the literature and has shown to produce positive 
outcomes for women. For example, women who received contraceptive counseling, especially 
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from their primary care provider, were more likely to have used contraception during their last 
intercourse (Lee, Parisi, Akers, Borrerro, & Schwarz, 2011). The counseling alone was shown to 
increase contraceptive use with even higher rates of usage if a contraceptive was prescribed at 
the visit (Lee et al., 2011). In addition, women who received contraceptive counseling from their 
primary care providers reported they were both satisfied and well informed after the visit, 
perhaps due to shared decision-making (Lee et al., 2011). Shared decision-making was an 
effective method of counseling primary care providers often used to manage other chronic 
illnesses (Ferguson et al., 2016). Overall, primary care providers were well suited to provide 
effective contraceptive counseling.  
 Despite the effectiveness of contraceptive counseling, attempts to increase contraceptive 
counseling rates when prescribing teratogenic medication had mixed outcomes. In one study, a 
clinical decision support tool inserted into the EHR to alert providers of a teratogenic 
prescription produced insignificant provider behavioral change (Schwarz et al., 2012). However, 
the intervention did not address evidence-based barriers such as provider education about 
contraception counseling, alternatives to teratogens, or contraception methods (Dirksen et al., 
2014; Schwarz et al., 2012; Shroff et al., 2017). Instead, 13% of the time, the provider replaced 
the teratogenic medication with another teratogenic medication (Schwarz et al., 2012). 
Therefore, the providers did not have the knowledge to choose a safer alternative medication. 
Despite lack of evidence in the EHR, providers reported that the clinical decision support tool 
made them more likely to discuss risks of medication, prescribe birth control, and provide 
preconception counseling (Schwarz et al., 2012). Other studies have reported similar 
discrepancies between the absence of change in the medical record compared to provider or 
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patient-reported behavioral change (Schwarz et al., 2013; Shroff et al., 2017). This may be due to 
a paucity of easy ways to document contraceptive counseling and pregnancy risk education.  
The TARCC framework was developed by Shroff et al. (2017) to address provider-
identified barriers to contraceptive counseling. The TARCC acronym stands for: is the 
medication teratogenic, is there a safe alternative, have you discussed the risks to pregnancy 
while on the medication, is the patient currently on or have you discussed and prescribed 
contraception, and has the counseling and risk education been charted (Shroff et al., 2017). It 
was used both as an educational tool and an EHR support tool (Shroff et al., 2017). TARCC 
helps providers go through specific steps when prescribing a new medication that is potentially 
teratogenic (Shroff et al., 2017).  
The QI project leader, Dr. Shroff, approved the use of the TARCC framework in this 
DNP project. When the framework is used to educate providers, it trains them to use shared 
decision making to provide contraceptive counseling (Ferguson et al., 2016; Lee et al., 2011; 
Shroff et al., 2017). The last step in the framework is to chart the counseling in the EHR. This 
step was based on literature reports about missing documentation. Overall, evidence supported 
the intervention to educate providers about teratogenic pregnancy risk counseling, contraceptive 
counseling, and non-teratogenic alternatives. 
Limitations of Literature Review Process  
 One limitation was the lack of randomized control trials that tested interventions to 
improve contraceptive counseling when prescribing teratogenic medication. Also, the sample 
sizes were often small. Studies were more likely to explore whether counseling was done and 
how often teratogenic medication was prescribed, not to improve outcomes. Also, survey 
responses in the articles were moderate to low. Thus, response bias was possible. Interventions 
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were limited to adding reminders and hard stops to the EHR rather than addressing provider 
barriers to knowledge and competency. Last, several studies focused on lupus, cancer, or 
epileptic patients which are not solely managed in primary care. Therefore, some findings were 
not from primary care managed chronic diseases.  
Discussion  
Conclusion of findings. Evidence illustrated the widespread lack of contraceptive 
counseling when primary care providers prescribed teratogenic medications. Yet, primary care 
providers manage chronic conditions that frequently require teratogenic medications. Providers 
reported a lack of knowledge about non-teratogenic alternatives, contraceptive counseling, and 
pregnancy risk counseling as barriers. Interviews with primary care clinic providers in urban NC, 
revealed they had no system in place to flag teratogenic medications or chart contraceptive 
counseling when they prescribe them (M. Felton, personal communication, August 20, 2019). 
The site’s practice aligned with the evidence about provider barriers to teratogenic safety. In 
addition, preliminary data from the primary care clinics’ EHR indicated that over half of the 
women were not using birth control while on a teratogen. Also, in three months, 30 to 50% of 
childbearing age women were using at least one teratogenic medication (D. Allen, personal 
communication, June 27, 2019). Thus, the TARCC framework was used to address provider 
barriers and improve teratogenic medication safety (Shroff et al., 2017).  
Contraceptive counseling that uses CDC Medical Eligibility Criteria aligned with 
recommendations from ACOG, AAFP, ACP, ASRM, and NPWH for primary care providers 
(ACOG & ASRM, 2019; Women's Preventive Services Initiative, 2016). Contraceptive 
counseling to all childbearing age women at wellness visits, especially if teratogenic medication 
is prescribed, is a best, ethical practice (ACOG & ASRM, 2019; Women's Preventive Services 
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Initiative, 2016). By using the FDA’s new pregnancy and lactation labeling rule, providers were 
equipped with pregnancy risk and teratogenic information to adequately counsel patients (FDA, 
2014). In addition, decreasing fetal exposure to teratogens aligned with Healthy People 2020 
goals (USDHHS, n.d.).  
Advantages and disadvantages of findings. Education of providers has been shown in 
the literature to be an essential requirement to increase rates of contraceptive counseling 
(Dirksen et al., 2014; Shroff et al., 2017). Therefore, the intervention of provider education had 
evidence to support it. The new FDA pregnancy and lactation labeling rule was gradually 
changing the way providers make clinical decisions about prescriptions for potentially 
reproductive women (FDA, 2014). The FDA rule helped providers have a clearer understanding 
of risks and benefits for counseling women (FDA, 2014). Last, providing contraceptive 
counseling when prescribing teratogenic medication not only had ethical implications, but 
aligned with national organizational recommendations. The providers at the primary care sites 
belonged to several of these organizations. It was also in line with national preventive health 
goals. Overall, providers had incentive to participate in the DNP project.  
The major disadvantage was that implementation of a clinical decision support tool into 
the EHR did not improve outcomes to increase contraceptive counseling (Schwarz et al., 2012). 
Yet, the intervention did not include provider education or educational resources, which were 
cited as significant barriers to increasing counseling rates. Also, the outcomes of the TARCC 
framework in the EHR were still being studied at the time of the literature review. Lack of 
randomized control trials to test interventions that increased pregnancy risk and contraceptive 
counseling was a disadvantage. However, provider education was supported by providers’ 
informal interviews at the project site and barriers cited in the literature. Overall, the education 
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session and phrase to document the TARCC framework in the EHR were practical interventions 
to improve outcomes.  
Utilization of findings in practice change. The evidence indicated that merely placing a 
decision-tree and alert in the EHR was ineffective for practice change (Schwarz et al., 2012). 
Also, providers requested continuing education on contraceptive counseling and teratogenic 
pregnancy risk counseling (Dirksen et al., 2014; Shroff et al., 2017). Therefore, the education 
session was in person with a follow-up email for links to outside resources for future reference. 
Topics for the session included commonly prescribed teratogenic medications, alternatives, risk 
counseling, and contraceptive counseling strategies (Callegari et al., 2015; DiPietro Mager et al., 
2018; Mody et al., 2015; Schwarz et al., 2012; Schwarz et al., 2013). EHR data and provider 
surveys were used to track outcomes. The surveys assessed provider perception of behavioral 
change about the TARCC framework because evidence showed a discrepancy between EHR 
outcomes and provider perceptions (Schwarz et al., 2012).  
Summary  
 Contraceptive counseling when teratogenic medications are prescribed reduces 
unintended pregnancy rates and fetal exposure to teratogenic medication. Healthy People 2020 
had a goal of increasing intended pregnancy rates in the United States from 51% to 56% 
(USDHHS, n.d.). Contraception is the most effective way to decrease unintended pregnancy. It 
should be available to all women at a low cost and discussed at all health promotion visits. 
(ACOG & ASRM, 2019; Women's Preventive Services Initiative, 2016). Birth defects and 
abortion secondary to fetal exposure to teratogenic medication were also among Healthy People 
2020 goals to decrease maternal and infant morbidity and mortality (Finer et al., 2005; 
USDHHS, n.d.).  
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 The DNP project was also related to Triple Aim goals (Institute for Healthcare 
Improvement [IHI], 2019). Contraceptive counseling improves patient experience through shared 
decision making. It equips patients with information needed to make healthy choices for their 
families. Patients will feel well informed about the risks of their medications and how to safely 
avoid pregnancy while on those medications. Birth defects were responsible for $2.6 billion in 
NC hospital costs. Also, abortions are costly to families who need them (NBDPN, 2010). 
Therefore, reducing the frequency of birth defects or abortions by minimizing fetal exposure 
would improve per capita healthcare cost: part of Triple Aim (IHI, 2019). Last, population health 
improves when families can plan a pregnancy, and when babies are born without birth defects or 
developmental disabilities. This DNP project’s long-term outcomes could improve population 
health when the TARCC framework is widely used at the project sites.  
Chapter Three:  Theory and Concept Model for Evidence-based Practice  
 Three key concepts of the DNP project were teratogenic medication, contraceptive 
counseling, and unintended pregnancy. Each concept was explored and defined using the 
literature and its specific applicability to the project was discussed (see Appendix C for DNP 
Project Concept Map). In addition, the DNP project was supported by a theoretical framework 
and evidence-based change model. Dorothea Orem’s theory of self-care underlies the rationale 
and content of the project, whereas Kurt Lewin’s Change Theory supported the method and 
format of the intervention.  
Concept Analysis  
Teratogenic medication. The first concept was teratogenic medication. A teratogenic 
medication has a high risk of harming the growth and development of the fetus if the mother uses 
the medication during pregnancy (FDA, 2014). Teratogenic effects include cardiac defects, 
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neural tube defects, facial clefts, learning disabilities, miscarriage, fetal death, and growth 
restriction (Bhakta et al., 2015; Briggs et al., 2015; DiPietro Mager et al., 2018). Before 2015, 
the FDA assigned a category to each medication to denote the level of teratogenicity (FDA, 
2008). Category C medications had limited data indicating the potential for fetal risk. However, 
the benefits often outweighed the risks (FDA, 2008). Categories D and X had the highest 
likelihood of teratogenicity based on human and animal studies, with X being contraindicated 
during pregnancy (FDA, 2008). As of 2015, the new Pregnancy and Lactation Labeling Rule 
replaced the letter categories with a narrative of potential risks, benefits, study data, and 
recommendations for women and men of reproductive potential for each medication (FDA, 
2014). Therefore, part of the teratogenic medication definition included the use of these 
guidelines to discuss risks and benefits with women.  
 In the literature, teratogenic medications were defined as class D and X medications 
despite the recent change in FDA labelling (Bhakta et al., 2015; Goyal et al., 2015; Mody et al., 
2015; Schwarz et al., 2005; Schwarz et al., 2012; Schwarz et al., 2007; Shroff et al., 2017). Study 
authors typically focused on the following teratogenic drugs: benzodiazepines, angiotensin-
converting enzyme inhibitors, angiotensin receptor II antagonists, anticonvulsants, certain 
antibiotics, statins, lithium, isotretinoin, paroxetine, and warfarin (DiPietro Mager et al., 2018; 
Mody et al., 2015; Schwarz et al., 2005; Shroff et al., 2017). For the DNP project, teratogenic 
medication was defined as category D or X medications in the following classes: 
benzodiazepines, angiotensin-converting enzyme inhibitors, angiotensin receptor II antagonists, 
anticonvulsants, statins, and warfarin. These classes helped provide focus to ensure the project 
was manageable.  
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Contraceptive counseling. Contraceptive counseling is a shared decision-making 
process between a provider and patient that allows the woman to choose the best contraceptive 
option for her at that time given her values and preferences (Dehlendorf, Krajewski, & Borrero, 
2014; Gavin et al., 2014). It includes risks, benefits, efficacy, method of use, and side effects of 
contraceptive options as well as safety of the method based on her medical and social history 
(Dehlendorf et al., 2014; Gavin et al., 2014). The information provided during contraceptive 
counseling should be based on the CDC Medical Eligibility Criteria, and the FPNTC with the 
most effective forms of contraception discussed first (Gavin et al., 2014). All options should be 
made available to women, including referrals to providers who offer implants and intrauterine 
devices (ACOG, 2015). Counseling includes prescription of appropriate medication, plan for 
follow up, discussion of barriers to effective use, and sexually transmitted disease protection if a 
barrier method was not chosen (Dehlendorf et al., 2014; Gavin et al., 2014). 
Strategies for effective counseling included using open-ended questions, giving 
information in a non-judgmental manner, promoting discussion, and demonstrating 
trustworthiness and expertise (Dehlendorf et al., 2014; Gavin et al., 2014; Lee et al., 2011). 
Primary care providers know their patients’ cultural, medical, and social histories well. 
Therefore, they can tailor counseling to the individual. It is for this reason that counseling done 
by primary care providers was well received and increased contraceptive use (Lee et al., 2011).  
Unintended pregnancy. When a woman becomes pregnant while she is not purposefully 
trying to become pregnant, she is considered to have an unintended pregnancy. There are two 
types of unintended pregnancy; unwanted and mistimed (Finer & Zolna, 2016). Unwanted 
pregnancies occur if a woman never intended to become pregnant in the future (Finer & Zolna, 
2016). Alternatively, if a woman wanted a pregnancy later than at the time of conception, the 
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pregnancy is considered mistimed (Finer & Zolna, 2016). Women are at risk for unintended 
pregnancy if they do not believe they can get pregnant, are nonusers of contraception, are 
misusing contraception, and are sexually active (Mosher, Jones, & Abma, 2015). Therefore, to 
determine if a woman is at risk for unintended pregnancy, she must be asked about her current 
pregnancy desires, sexual activity, and contraception use. In 2011, 45% of live US births were 
unintended (Finer & Zolna, 2016). Additionally, 42% of unintended pregnancies ended in 
elective abortion (Finer & Zolna, 2016). Therefore, this is a widespread phenomenon that is not 
being sufficiently tackled in primary care. 
 Unintended pregnancy is used as an indicator of a woman’s reproductive autonomy and 
is deeply intertwined with the social determinants of health (Morse, Ramesh, & Jackson, 2017). 
Unfortunately, unintended pregnancy rates were proportionally higher in low income Black and 
Hispanic women (Finer & Zolna, 2016; Morse et al., 2017). This population of women was 
already at risk for poor outcomes such as low birth weight, inadequate prenatal care, and 
substance use, therefore, an unintended pregnancy can increase the risk even further (Finer & 
Zolna, 2016; Morse et al., 2017). Even though unintended pregnancy occurred in all religions 
and backgrounds, the phenomenon must be viewed through a cultural and social lens. Pregnancy 
may be viewed as an unplannable event or as something that happens when it is supposed to 
(Morse et al., 2017). Women may also not be in control of their contraceptive use yet may be 
welcoming of the pregnancy (Morse et al., 2017). Therefore, pregnancy is not always easily 
defined as unintended. Also, unintended pregnancy should not be correlated with unhappiness or 
lack of acceptance of the pregnancy. In the DNP project, pregnancy intentions were assessed by 
the provider upon teratogenic medication prescription. Pregnancy was considered unintended if 
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she chose to use the teratogenic medication and wished to abstain from pregnancy while on the 
medication. 
Theoretical Framework  
Naming the theory. Dorothea Orem’s theory of self-care provided the theoretical 
framework for the DNP project. Orem (2001) theorized that people perform self-care behaviors 
to promote their health and well-being. Individuals have varying levels of self-care agency, 
which encompasses their ability to carry out self-care behaviors (Orem, 2001). For example, 
finances, motivation, knowledge, sociodemographic status, and culture all impact a person’s self-
care agency (Orem, 2001).  Alternatively, self-care demands are a person’s self-care needs which 
are based on the patient’s situation at that time such as their health history, medications, and age 
(Orem, 2001). Orem (2001) postulated that a self-care deficit exists when a person’s self-care 
demands are greater than their self-care agency. Therefore, Orem (2001) stated that nursing’s 
role was to decrease self-care deficits to promote self-care behaviors in patients through nursing 
agency. 
To do this, nurses, as care agents, must first help patients investigate the need for self-
care and second, encourage them to decide to perform self-care behavior (Orem, 2001). Also, 
strategies such as teaching, guiding, and supporting build up patients’ self-care agency and thus 
decrease self-care deficit (Orem, 2001).  Anticipatory guidance is also used to help the patient 
prepare to overcome barriers in maintaining self-care in the future (Orem, 2001). At that point, 
the patient takes the final step, which is deliberate action to perform the self-care behavior 
(Orem, 2001). Orem (2001) developed three categories of self-care requisites: universal, 
developmental, and health deviation. Health deviation requisites are the most applicable to the 
DNP project as they are related to specific health conditions (Orem, 2001). For instance, new 
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self-care behaviors are needed with changes in medical history, current medications, age, or risk 
factors (Orem, 2001). For example, if a female patient with a family history of breast cancer 
turns 40, the self-care behavior of routine mammograms should be discussed with the patient.  
 Orem’s theory of self-care has been used in research to improve self-care knowledge, 
behaviors, and outcomes in patients with diseases such as migraines, diabetes, hypertension, and 
coronary artery disease (Helou, Talhouedec, Shaha, & Zanchi, 2016; Johansson, Adamson, 
Ejdeback, & Edell-Gustafsson, 2014; Mahmoudzadeh Zarandi, Raiesifar, & Ebadi, 2016). The 
theory was used in each study to create self-care assessment tools, self-care education sessions, 
or individualized nursing interventions to increase self-care behavior and disease outcomes 
(Helou et al., 2016; Johansson et al., 2014; Mahmoudzadeh Zarandi et al., 2016). Experimental 
groups exposed to self-care strategies based on Orem’s theory had improved outcomes compared 
to control groups (Helou et al., 2016; Johansson et al., 2014; Mahmoudzadeh Zarandi et al., 
2016).  
Application to practice change. Women are often ill-equipped to make self-care 
decisions to reduce unintended pregnancy. As discussed in the literature review, women do not 
receive pregnancy risk counseling or contraceptive counseling when teratogenic medications are 
prescribed. Therefore, women may not know there is a self-care demand to prevent pregnancy 
while on the medication. The risks of teratogenesis and unintended pregnancy raise self-care 
demand. A lack of knowledge about pregnancy risk and safe methods of contraception decrease 
self-care agency. A self-care deficit is apparent. The role of nursing and more broadly, that of 
primary care providers, is to reduce the self-care deficit and promote self-care agency. Therefore, 
the DNP project used Orem’s theory of self-care to reduce fetal exposure to teratogenic 
medication.  
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Providing contraceptive counseling to women prescribed teratogenic medication was an 
implementation of Orem’s theory of self-care. The use of the TARCC framework illustrated each 
step of the theory: investigating, decision making, and deliberate action. The provider first 
investigated whether the new medication is teratogenic and if there is an alternative. If the best 
option for the patient is the teratogenic medication, the provider must realize there is now a need 
for self-care behavior, specifically prevention of pregnancy. This is an example of a health 
deviation requisite for self-care. Discussing pregnancy risk with the patient introduced the idea 
that self-care measures are necessary to prevent fetal exposure. The investigation was continued 
by assessing the woman’s plan for reproduction and thoughts on contraception.  
The following step of contraceptive counseling represented the decision-making process 
and provider intervention to reduce self-care deficit. The discussion of risks, benefits, side 
effects, and efficacy increased the patient’s self-care agency by adding to the patient’s 
knowledge and ability to make an informed decision. Anticipatory guidance about barriers to the 
correct use of each method further increased self-care agency by helping the patient develop 
strategies to avoid those barriers. For example, how can she remember to take her oral 
contraceptive pill daily and what to do if she misses one. Counseling should include an 
exploration of the patient’s culture, finances, and social norms to ensure the method chosen fits 
into the person’s lifestyle. This is yet another example of promoting self-care agency and 
reducing the self-care deficit. Overall, counseling enhances the decision to use birth control 
correctly while on teratogenic medication, thus promoting patient self-care behavior.  
Evidence-Based Practice Change Theory  
 Change model. Kurt Lewin’s Change Theory was used to support the change in 
provider behavior in the DNP Project. Lewin developed the theory in the early 20th century to 
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address social change. He theorized that behavior exists at equilibrium within a forcefield, with 
equal driving and restraining forces (Lewin, 1947). The forces act as a balance scale, keeping the 
behavior from changing unless the level of restraining or driving forces changes (Lewin, 1947). 
Driving forces push change by increasing tension, whereas restraining forces oppose change 
(Lewin, 1947). Therefore, to produce behavior change, an intervention either needs to increase 
driving forces or reduce restraining forces (Lewin, 1947).  
 However, changing behavior is not enough to sustain the behavior. Therefore, Lewin 
added the act of unfreezing and refreezing to the theory (Lewin, 1947). Unfreezing has the 
following components: identifying the driving and restraining forces, recognizing the need for 
change, increasing motivation and confidence, and planning for change (Lewin, 1947). 
Refreezing ensures the new behavior is sustained in a new equilibrium (Lewin, 1947). Drivers of 
refreezing include building the new behavior into the culture or social norms and reducing 
factors that could allow the behavior to regress to the former state (Lewin, 1947). 
It is also important to work with a group during the unfreezing and refreezing phases 
rather than individuals (Lewin, 1947). Lewin (1947) postulated that group motivation and 
decision to change have a higher likelihood of sustainability than individual decisions. Groups 
can affect social values and norms, thus making the new behavior more likely to refreeze 
(Lewin, 1947). Also, individuals tend to act as group members rather than based on personal 
preferences when making decisions (Lewin, 1947). Therefore, group decisions are more likely to 
stick as individuals are less likely to regress regardless of their personal thoughts on the new 
behavior (Lewin, 1947).  
Application to practice change. Lewin’s Change Theory supported the intervention in 
the DNP project. First, the literature review revealed driving and restraining forces that impact 
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teratogenic prescription and contraceptive counseling. This was an essential step in the 
unfreezing process and in planning an effective intervention. For example, providers’ lack of 
knowledge about teratogenic alternatives, pregnancy risk counseling, and contraceptive 
counseling were restraining forces inhibiting change. Therefore, providing education reduced 
restraining forces and tipped the scale towards behavior change. 
Similarly, the TARCC framework reduced restraining forces by helping the providers 
remember each step of the decision tree to ultimately reduce fetal teratogenic exposure. Also, the 
outdated FDA pregnancy risk categories were restraining factors due to their lack of 
comprehensive teratogenicity information. For this reason, the updated pregnancy and lactation 
labeling rule was discussed with the providers to equip them with better pregnancy risk 
information. Again, this reduced a restraining factor and made behavior change more likely. Not 
only was reducing restraining factors necessary but also increasing driving factors to promote 
change.  
Examples of driving factors were professional organization recommendations, cost 
savings, ethical ramifications, improved patient outcomes, and national goals. These driving 
forces were used during the education session to highlight the importance of reducing fetal 
exposure to teratogenic medication and unintended pregnancy. Another piece of Lewin’s theory 
utilized in the intervention was group motivation and decision to change. The education was 
done with a group of providers at two primary care practices rather than with an individual. If the 
group of providers decides to implement the practice change, it will be more likely that the 
change will be refrozen and will override individual resistance to change. Also, if this group of 
providers successfully implemented the change, the intervention could be spread to other groups 
of primary care providers in the network. This would allow for a systems-level change thus 
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further improving the likelihood of sustainability. An additional driver of refreezing was the 
potential to include the TARCC framework in the health record, thus making it part of the 
existing system in that office. Overall, the DNP project intervention increased the awareness of 
driving forces and decreased restraining forces to reduce fetal exposure to teratogens and 
unintended pregnancy.  
Summary  
 Teratogenic medication, contraceptive counseling, and unintended pregnancy were 
essential concepts in the DNP project. To be consistent with the literature, teratogenic 
medication was defined as category D and X medications. The concept of contraceptive 
counseling included the content as well as the methods of counseling. Shared decision making, 
open-ended questions and eliciting patient preferences were essential to effective counseling. 
Also, counseling must be holistic to include risks, benefits, and efficacy of all method options 
using evidence-based contraception information. Lastly, unintended pregnancy was a 
complicated phenomenon that has reproductive, health, social, financial, and cultural 
ramifications. In the DNP project, if a woman chose to take teratogenic medication and avoid 
pregnancy, a subsequent pregnancy was considered unintended.  
 Orem’s theory of self-care and Lewin’s change theory both underlined the content and 
format of the DNP intervention. A woman’s self-care agency was increased when she had 
pregnancy risk and contraceptive knowledge. By reducing her self-care deficit, she would have 
the ability to make an informed, deliberate decision to avoid pregnancy while on teratogenic 
medication. Also, Lewin’s theory further supported the success and sustainability of the 
intervention by using a group education session, highlighting driving factors, and reducing 
restraining factors.  
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Chapter Four:  Pre-implementation Plan 
In the pre-implementation phase of the DNP project, it was essential to consider 
organizational readiness, approval procedures, cost-benefit analysis, outcome measurement, and 
interprofessional collaboration. The organizational approval and institutional review board (IRB) 
processes was explored for the project site and ECU. Interprofessional team members were 
essential to the approval process and continued to serve on the interprofessional team for 
implementation. Also, outcomes were developed to evaluate the project. The security of patient 
health information was also outlined.  
Project Purpose 
 The purpose of the DNP project was to increase primary care provider knowledge and 
use of the TARCC framework at two urban clinics in NC (Shroff et al., 2017). Using the TARCC 
framework increased the safety of medication prescription to childbearing age women (Shroff et 
al., 2017). The first long-term outcome of the project was a reduction in teratogenic prescriptions 
to childbearing age women. The second outcome was increased contraceptive use when a 
teratogenic medication is used by childbearing age women. The outcomes of the DNP project 
aligned with Healthy People 2020 goals to reduce birth defect rates, infant mortality, and 
unintended pregnancies (USDHHS, n. d.)  Additionally, a reduction in these three conditions 
could improve population health and healthcare costs, in alignment with the Triple Aim (IHI, 
2019).  
Project Management 
Organizational readiness for change. Organizational leadership was committed to 
providing excellence and safety in patient care. The DNP student met with senior leadership who 
thought all primary care providers should receive education about TARCC. They were 
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committed to project sustainability by ensuring TARCC was shared with all practices after the 
project was complete. The DNP student also met with practice providers at two clinics who 
stated there were no safety measures when prescribing teratogenic medication to childbearing 
age women (M. Felton, personal communication, August 20, 2019; M. Fike, personal 
communication, June 27, 2019). The providers also reported they did not routinely consider 
whether a medication was teratogenic and therefore, did not co-prescribe contraception (M. 
Felton, personal communication, August 20, 2019; M. Fike, personal communication, June 27, 
2019). Both practice medical directors agreed with the DNP project goals and were willing to 
allocate provider meeting time to the project. Last, organizational data showed a need for the 
project because 55-60% of sexually active women at the site who received a teratogenic 
medication had no recorded contraception (D. Allen, personal communication, Jan 29, 2020). 
Interprofessional collaboration. Four team members essential to project success were 
the health center administrator (HCA), two practice medical directors, and an FNP at one of the 
sites. At site A, the HCA provided project site approval. He was responsible for clinic 
improvement projects and led monthly provider meetings. He gave the DNP student time at two 
provider meetings to introduce the project and to implement the education session. The practice 
medical director at each clinic evaluated the project from a provider perspective and to ensure it 
aligned with evidence-based practice. Both directors were FNPs at their practice site. Therefore, 
they were instrumental in bringing other practice providers on board with the project. The 
director at site B gave the DNP student time at provider meetings for introductions and the 
education session. Last, an FNP was the site champion for site A and helped engage other 
providers in the project. She also provided feedback on the project during the planning stage. 
During project implementation, this FNP took over as the practices’ medical director.  
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Risk management assessment. A strengths, weaknesses, opportunities, and threats 
analysis (SWOT) was completed to assess project risks.  
Strengths. The primary project strength was clinic staff buy-in at site A. Another strength 
was that the DNP student already had a positive working relationship with the clinic staff at site 
A from a prior clinical rotation. A third strength was alignment of organizational safety and 
excellence values with project outcomes. Clinic baseline data showed that less than half of 
patients used contraception while on teratogenic medication. This data gave providers an 
incentive for change, which increased the chance of project success. Finally, organizational 
leaders and an FNP at one of the sites were involved in project development and approval, which 
further increased the likelihood of successful implementation.  
Weaknesses. One potential project weakness was the inability to use medical assistants 
(MAs) during implementation. Both clinics had a high rate of support staff turnover. Therefore, 
the administration thought additional tasks for the MAs would be burdensome. Consequently, the 
project was entirely provider driven. Providers had competing demands to see high numbers of 
patients and meet quality metrics. Their competing demands may supersede project goals. 
Additionally, site B was saturated with quality improvement projects and were not as involved in 
the planning stage of the DNP project. Therefore, site B providers were less inclined to fully 
participate in the DNP project. To use the TARCC framework, providers must spend more time 
prescribing medication or discussing pregnancy risk and contraception use. With short patient 
visits, this may be a challenge to implementation. Last, the organization had a complicated IRB 
process which excluded the DNP student from accessing the electronic health record. Therefore, 
all data outcomes were extrapolated by the Director of Nursing Research & Evidence-Based 
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Practice. Relying on a third party to pull data could delay data collection thus delay project 
outcome evaluation.  
Opportunities. The project's foremost opportunity was its alignment with national goals 
and professional organization recommendations (ACOG & ASRM, 2019; Women's Preventive 
Services Initiative, 2016). Further, some states outlawed abortion or decreased the gestational 
age at which it is legal. Therefore, a project which reduces the need for an abortion by preventing 
unintended pregnancy aligned with current policy changes. Last, there was an opportunity to 
expand the project to other network primary care sites and integrate TARCC into the medical 
record.  
Threats. Project threats included a conservative patient population at site A that may be 
unreceptive to contraception use. Thus, despite an increase in contraceptive counseling, there 
may not be an increase in contraception use. Also, few medications may be prescribed during the 
three-month implementation window, thus threatening TARCC framework use. Last, the FDA's 
new pregnancy labeling rule may obscure which medications are teratogenic. Changed labeling 
rules may complicate provider decision- making since there are no longer strict medication 
categories. With the new rules, providers may need to spend more time researching pregnancy 
risk, which lengthens provider visit times.  
Organizational approval process. The DNP student initiated a professional relationship 
while working in the urgent care attached to site A. At that time, the HCA covered urgent care 
and primary care. Therefore, discussion about the DNP project occurred early with the HCA and 
the FNP, who would become the project champion and eventually the site medical director. Both 
stakeholders provided feedback on the project, outcomes measurements, and whom to meet for 
approval in the organization. The DNP student was referred to the Director of Nursing and 
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Patient Care Services. This individual gave feedback and advice on whom next to meet for 
project approval. A meeting with the Director of Nursing Research & Evidence-Based Practice 
solidified outcomes' measurements and initiated the formal, organizational approval process.  
First, the organizational feasibility form was completed and signed by the Director of 
Nursing Research & Evidence-Based Practice. At that point, it was sent to the new HCA at site 
A. Both the HCA and practice medical director approved the project (see Appendix D for Clinic 
Site Letters of Approval). The biggest approval process challenge was meeting with the Director 
of Nursing and Patient Care Services, Associate Chief Nursing Officer, and Associate Chief 
Medical Officer for Innovation and Improvement. These organizational leaders were essential to 
project planning and were required to sign the feasibility form before project approval. The 
leaders recommended that a second clinic be included in the DNP project, site B. The DNP 
student was referred to the practice medical director for site B who also approved the project (see 
Appendix D for Clinic Site Letters of Approval). After being approved by organizational leaders 
and both clinics, the proposal was reviewed by the Vice President of Patient Care and System 
Chief Nurse Executive for final approval.  
Information technology. Baseline and outcomes data were pulled from Duke Enterprise 
Data Unified Content ExplorerTM (DEDUCETM). DEDUCETM extracted data from the Epic 
Electronic Health Record without directly accessing patient records. The Director of Nursing 
Research & Evidence-Based Practice used DEDUCETM rather than the DNP student. BoxTM, a 
cloud content sharing service on the organization’s server, was used to send data to the DNP 
student. Also, Microsoft Excel was used to manipulate the data from DEDUCETM to derive 
baseline and outcomes metrics. Excel was also used to create tables, graphs, and figures to 
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present the data after implementation. Last, during the education session, Microsoft PowerPoint 
was used to display the session’s content.  
Cost Analysis of Materials Needed for Project 
 The significant costs of the project were paper materials and food (see Appendix E for 
DNP Project Budget). The estimated total cost of the project was under $350. Each provider 
received a toolkit with educational materials during the session, which contributed to cost. 
Additional costs included provider time doing surveys, which is estimated at 25 minutes, and a 
one-hour education session. Implementing the TARCC framework also added time to the visit if 
the provider performed pregnancy risk and contraceptive counseling. However, cost savings 
related to reduced fetal exposure to teratogens made the project benefits outweigh its costs.   
 Savings from one abortion prevention would yield a net benefit from this project. On 
average, women spend between $450 and $550 for a first-trimester abortion and between $750 
and $5,000 for a 20-week abortion in the US (Jerman & Jones, 2014). Therefore, savings from 
one abortion is more than project costs. Last, there is the emotional cost of an abortion that could 
occur for some women that would be prevented.  
Similarly, one birth defect prevention saves healthcare dollars from birth until death. For 
example, the US spends an estimated $2.6 billion on hospital costs for children with birth defects 
each year (NBDPN, 2010). Therefore, the estimated yearly hospital cost of one child with a birth 
defect is $78,000 (NBDPN, 2010; Parker et al., 2010). Overall, savings accrued from preventing 
one abortion or birth defect significantly outweigh the project costs. 
Plans for Institutional Review Board Approval 
 The project site and ECU had an IRB process for all quality improvement and research 
projects. At the project site, the process began with a completed organizational feasibility form 
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that was signed by all stakeholders for the project, including the Director of Nursing Research & 
Evidence-Based Practice. Once approved, the Director submitted the feasibility form to the 
institution’s IRB. The DNP project was deemed quality improvement since it did not meet the 
research definition and was approved for implementation (See Appendix F for Site IRB 
Approval Form).  
The DNP student also completed the IRB Program Evaluation Self-Certification Process 
through ECU. Because this project was quality improvement, the self-certification process 
indicated that a full IRB review was not required (See Appendix G for ECU IRB Approval 
Form). The DNP student also completed the Collaborative Institute Training Initiative course for 
Social and Behavioral Research Investigators in Human Research. The course ensured that best 
research practices were followed to ensure no harm to participants. Modules were completed 
both for ECU and for the practice site.  
Plan for Project Evaluation 
Demographics. Two aspects of demographic data were collected (see Appendix H for 
Data Collection Tools). The first piece of demographic information was the professional role of 
the participant: MD, NP, or PA. The data were reported as a percentage of the participants. The 
results were presented in a pie chart to illustrate the makeup of the participants in the education 
session. The second piece of demographic information was the number of years of primary care 
experience for each participant. This data was reported as a mean with a standard deviation and 
range.  
Knowledge outcome measurement. The first outcome measure was an increase in 
provider self-reported competency in using the TARCC framework. Providers also rated how 
likely they were to use the TARCC framework in the future. Increased future framework use 
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likely indicated increased provider competence in using TARCC as well as their perceived 
importance of the framework in improving the quality of their care. Therefore, increased future 
use of the TARCC framework was used as an indicator of increased provider knowledge and 
competency.  
Evaluation tool. A DNP student-created data collection tool was used to evaluate 
TARCC framework knowledge (see Appendix H for Data Collection Tools). Providers 
completed a data collection tool at three points during the project. First, during the first week of 
implementation, second at mid-implementation, and finally after completion of the project. The 
preliminary tool, given after the education session, included two demographic questions, two 
knowledge uptake questions, two competency questions, and one future behavior question. The 
mid-implementation tool contained one question to assess the frequency of TARCC use, one 
future behavior question, one knowledge uptake question, one competency question, and one 
open ended question. The final tool included one competency question, one frequency of use 
question, one future behavior question, and several questions about sustainability and evaluation. 
The tools allowed the student to capture similar information at three time points without placing 
a burden on providers.  
Data analysis. Before the project, the providers did not use the TARCC framework and 
did not know the framework. There were no national benchmarks for TARCC usage. Providers’ 
knowledge and competence in TARCC framework use was therefore simply tracked over the 
course of implementation to evaluate for change and to guide improvement measures. However, 
no numeric goal was set for the rate of improvement because there was no current national or site 
benchmark.  
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Additionally, a report with the number of times the TARCC framework dot phrases were 
documented in the EHR was supposed to be pulled weekly by the Health Center Administrator. 
However, this report was deemed not possible by the site IT team.  
Data management. The data collection tool results were placed into Excel for 
manipulation. There was no personal health information on the surveys. The excel file with 
results was saved on the DNP student’s personal computer. Hard copies of the surveys were kept 
by the DNP student in a folder as the primary storage method. The secondary method of storage 
was scanned copies of the completed surveys on the student’s personal computer. Both the excel 
file and scanned copies were saved on an external hard drive. Data will be kept for two years. 
After two years, the surveys will be shredded, and the electronic files deleted.  
Long-term outcome one. The first long-term outcome was the percentage of sexually 
active, childbearing age women without contraception while on a teratogenic medication. One 
year before implementation, 56% of women aged 18 to 50 seen at clinic A were not using 
contraception while on a teratogen (D. Allen, personal communication, Jan 29, 2020). Clinic B 
had a similar percentage of 57% (D. Allen, personal communication, Jan 29, 2020). This was a 
long-term project outcome because increased TARCC use would lead to increased contraceptive 
counseling. Ideally, increased counseling would lead to an increase in patient contraception use. 
This outcome should lead to a reduction in birth defects, unintended pregnancy, and the need for 
an abortion.  
Evaluation tool. The Director of Nursing Research & Evidence-Based Practice obtained 
the baseline data using DEDUCETM. The outcome data was collected one month after the end of 
the project because DEDUCETM information lagged 30 days behind provider-patient encounter 
dates. The DNP student used Excel to merge the reports for contraceptive use, sexual activity, 
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and medication use. A pivot table in Excel enabled the DNP student to extract the percentage for 
the outcome metric. The denominator was the number of women, age 18 to 50, seen in Fall 2019 
who reported they were sexually active and had a teratogenic medication in their active 
medication list. The numerator was the number of women who reported they were using a form 
of contraception.  
Data analysis. There was no national or site benchmark for the long-term outcome 
therefore there was no exact goal percentage. However, baseline data from one year before 
implementation showed a 56% and 57% rate, respectively showing room for improvement. 
Therefore, the goal was to decrease this percentage by any amount. The metric was calculated 
for a three-month window one year prior to implementation and during implementation for 
comparison.  This metric improvement relied on proper data input into the EHR regarding 
current sexual activity, medication reconciliation, and contraceptive documentation. Therefore, 
this outcome was not solely a byproduct of the TARCC framework use. Over time, the outcome 
should continue to decrease as providers use the TARCC framework in daily practice. A large 
change in this metric is not expected by the end of implementation.  
Long-term outcome two. The second long-term outcome was a reduction in the 
percentage of childbearing age women taking a teratogenic medication. In the Fall of 2018, 33% 
of the women aged 18 to 50 who attended clinic A had a teratogenic medication on their 
medication list. Clinic B had a higher percentage at 50%. A reduction in this number represents 
the successful use of the TARCC framework because it implies a teratogenic medication was 
changed to a safer alternative.  
Evaluation tool. Similar to outcome one, the Director of Nursing Research & Evidence-
Based Practice gathered the data from DEDUCETM. Excel was again used to manipulate the data 
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to find the outcome result. The data was pulled 30 days after project completion. The 
denominator was the number of women, aged 18 to 50, seen in Fall 2019. The numerator was the 
number of women who had a teratogenic medication listed in their active medication list. The 
classes of teratogenic medications included were benzodiazepines, angiotensin receptor blockers, 
angiotensin-converting enzyme inhibitors, anticonvulsants, statins, and warfarin.  
Data analysis. There was no national benchmark for the percentage of childbearing age 
women taking a teratogenic medication. The goal was therefore to decrease the percentage by 
any amount and not to meet a specific target. Again, this data was evaluated for a three-month 
window one year prior to implementation and during implementation. There were two ways to 
improve this metric. The first way was a reduction in newly prescribed teratogens. During the 
education session, providers were encouraged to use the TARCC framework when prescribing a 
new medication to increase the use of safer alternatives. However, the outcome could also be 
improved by switching current medications to safer alternatives by doing a medication 
reconciliation. Due to the limited timeframe and scope of the DNP project, the education session 
did not focus on this. Therefore, there will only be a modest, if any, improvement in this long-
term outcome during the project. As the TARCC framework is used more consistently and MAs 
become involved, this outcome will more quickly improve. This may be a focus for future 
projects and to increase the sustainability of the project.  
Data management. The reports pulled from DEDUCETM had patient medical record 
numbers that were used to merge the files. There were no other patient identifiers or patient 
health information on the reports. The files were stored in secure cloud storage called BoxTM that 
was on the organization’s server in a file that was only accessible by the DNP student and 
Director of Nursing Research & Evidence-Based Practice. Once merged in Excel, a new 
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spreadsheet was made without any patient health information. This spreadsheet that contained 
only raw data with no patient health information was stored on the DNP student’s personal 
computer for manipulation. Therefore, the reports with medical record numbers were only saved 
in the organization’s secured server, thus protecting the private information. The de-identified 
excel sheet was saved on the student’s personal computer and an external hard drive. After two 
years, the de-identified excel sheet and DEDUCETM reports will be erased from the computer, 
external hard drive, and organizational server. If the DNP student leaves the organization before 
this time, the DEDUCETM reports will be moved to ECU’s departmental pirate drive, which is 
approved for electronic storage of personal health information.  
Summary 
 The project sites and critical stakeholders approved the DNP project. To receive 
approval, the DNP student met with organizational leaders such as the HCA, practice medical 
directors, FNP at the site, Director of Nursing Research & Evidence-Based Practice, Director of 
Nursing and Patient Care Services, Associate Chief Nursing Officer, and Associate Chief 
Medical Officer for Innovation and Improvement. These stakeholders were not only critical to 
the approval process but also in the planning stage of the project. Each person offered feedback 
to improve the project, which therefore increased the likelihood of success. Also, data at the 
project site illustrated an organizational readiness for the project. Less than half of the 
childbearing age women seen in Fall 2018 stated they were using contraception while on a 
teratogenic medication at both clinics. Finally, IRB approval was needed at both ECU and the 
project site. However, due to the quality improvement nature of the project, a full IRB was not 
needed at either site.  
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 The cost-benefit analysis of the project showed cost savings to be higher than the cost of 
the project. The project is estimated to cost less than $350. However, the savings from the 
prevention of one abortion or one birth defect could save $450-$5000 and $78,000, respectively. 
Time spent by providers is another cost of the project, both in using the TARCC framework 
during visits and in attending the education session and completing project surveys. However, it 
was expected that the project’s cost savings would outweigh the costs. 
 The purpose of the DNP project was to increase primary care provider knowledge of the 
TARCC framework. Therefore, the first outcome of the project was to increase provider 
knowledge. This was evaluated using data collection tools to test for competence, knowledge 
uptake, and future use of the TARCC framework. Providers completed the data collection tools 
at three points during implementation. Also, two long-term outcomes were selected to capture 
the desired effects of using the TARCC framework. The first long-term outcome was a decrease 
in the percentage of childbearing age women without contraception while on a teratogenic 
medication if they report they are sexually active. The second long-term outcome was a 
reduction in the percentage of childbearing age women taking a teratogenic medication. Data 
from DEDUCETM was used to evaluate the long-term outcomes. Importantly, patient data was 
secured on the organization’s cloud service, which is an approved method by the project site. 
Chapter Five:  Implementation Process 
 This chapter describes the DNP project sites, participants, and their engagement. The 
implementation process will be detailed, including variations throughout the project. Multiple 
plan do study act (PDSA) cycles were carried out at both sites throughout implementation. Each 
one will be explored in the timeline in which they occurred. 
Setting 
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          The DNP project setting was two primary care clinics within an extensive university 
hospital network. The clinics were non-profit and privately funded in an urban area in central 
NC. The clinics served patients with Medicaid, Medicare,  private insurance, and uninsured. The 
providers at the practices cared for patients of all ages. The clinics provided primary family care, 
including pediatrics. However, there were no obstetrical or gynecological services. Thus, the 
practices had no specialty providers, only general medicine physicians, PAs, and FNPs. Minor 
procedures, i.e., suturing, incision and drainage, and wart removal, were performed at the 
practices.  
 Medication reconciliation occurred at every primary care visit. Primary care providers 
frequently prescribe most medications young women receive. Therefore, the practices were 
dedicated to safe prescribing to childbearing-age women. Specifically, the practices wanted to 
ensure that women were either not prescribed teratogenic medication or did not become pregnant 
while on teratogens. Further, it was the primary care provider’s responsibility to coordinate care 
for the patient. For example, if a patient was prescribed a teratogen by another provider, the 
primary care provider should educate her about pregnancy risk and contraception. The practices 
had provider visits with 2,865 women of childbearing age over a three-month period one year 
before implementation (D. Allen, personal communication, June 27, 2019). This number of 
patients suggests that the TARCC framework could be used often for safe prescribing.  
Participants 
 Project participants were 14 primary care providers consisting of five FNPs, eight 
physicians, and one PA. Two FNPs, one at each site, were the practice medical directors. 
Inclusion criteria were that each participant was a project site primary care provider during 
implementation. Thus, all clinic providers were invited to participate in the education session. No 
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primary care provider was excluded from participation because each one cared for childbearing 
age women.  
Recruitment 
        The participants represented a convenience sample because they were all project site 
primary care providers. Recruitment of participants began by engaging the practices’ medical 
directors and Health Center Administrator for site A. At site A, an additional FNP was already 
engaged as the site champion. She had completed a DNP project and was a former clinical 
instructor and coworker. During implementation, this FNP took over as the practice medical 
director of site A. Next, the medical directors recommended that the DNP student introduce and 
receive feedback on the project at a provider meeting. Engagement and recruitment of the other 
providers occurred at these two provider meetings two months before project implementation for 
site A and one month before for site B.  
 At clinic A’s meeting, the providers showed interest in the project purpose and gave 
feedback to improve TARCC implementation. Most providers agreed their clinic had a problem 
because they had omitted contraception discussions while prescribing teratogenic medications. 
The providers stated the EHR should flag a reminder each time a teratogenic medication was 
prescribed. The providers’ biggest hesitation was the ability to remember to use TARCC and 
routinely document it in the EHR. Each provider requested frequent reminders throughout 
implementation. The providers requested a list of their patients who were on teratogenic 
medications without contraception. Because their requests were not part of the DNP project and 
would require further IRB and EHR access, the student could not comply. Their requests 
illustrated perceived project need and eagerness to improve the safety of teratogenic 
prescriptions.  
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 At the provider meeting at site B, providers also felt TARCC and its concepts were an 
essential part of safe care. However, providers were hesitant to incorporate more work into their 
daily practice due to high turnover and quality improvement burnout. Nevertheless, providers 
were eager to attend the DNP project education session and participate as much as possible 
during the project. The practice medical director at site B suggested a PA as the site champion. 
The PA was passionate about women’s health and was interested in helping the project succeed 
and therefore became the site champion for site B.  
Implementation Process  
Provider Education Sessions. The sessions were scheduled for one hour with 40 
minutes for didactic and 20 minutes for the preliminary data collection tool and questions (See 
Appendix H for Preliminary Data Collection Tool). The sessions at sites A and B were held 
during previously scheduled provider lunch meetings. At site A, the session was done during the 
first week of implementation, and it was cut short to 25 minutes due to a last-minute confidential 
provider meeting on the same day (See Appendix I for Site A PowerPoint Slides). Data 
collection tools were deferred to the week after the education session. All seven providers 
attended the education session as well as the Health Center Administrator. The education session 
at site B occurred one month after implementation started with all seven providers (See 
Appendix J for Site B PowerPoint Slides). Providers completed the preliminary data collection 
tool surveys immediately after the education session as planned. Results from the preliminary 
surveys were compared to the mid and final surveys to monitor for improvement. No numerical 
goal was set because there is no national benchmark or previous use of the TARCC framework.    
 The education session content was based on each step of the TARCC framework (See 
Appendix I and J for Education Session PowerPoint Slides). For example, determining if a 
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medication is teratogenic and choosing an alternative was included in the session.  To discuss 
effective contraceptive counseling, recommendations from the FPNTC and CDC were used. 
Further, literature review and baseline clinic data were used to discuss current practice gaps, both 
nationally and at the clinic. Last, connections between the project goals and current policy were 
discussed. Providers were given Teratogenic Medication Safety in Primary Care Toolkits to 
reinforce learning from the education session. The toolkit included session PowerPoint slides, 
U.S. Medical Eligibility Criteria Wheel, and Summary Chart, Birth Control Methods Options 
Chart, and a teratogen alternatives chart (CDC, 2016; FPNTC, 2019).  
Dot phrases. Dot phrases were quick ways for providers to document pre-written 
sentences using a one or two-word phrase in the electronic medical record. The site A champion 
helped create and share two dot phrases with all providers the week of their education session. 
These phrases allowed providers to document the TARCC framework in the EHR easily. The 
first phrase was “.teratogenalternative.” When the provider typed the dot phrase, the following 
statement appeared in the progress note: “A safer alternative medication has been chosen for this 
patient to avoid exposure to a potentially teratogenic medication.” The second dot phrase was 
“.teratogencounseling.” When this dot phrase was typed, the following statement populated the 
progress note: “The patient was adequately counseled on the risks of pregnancy while taking 
[blank for medication name]. Contraceptive counseling was performed to reduce the risk of 
pregnancy while on the medication. The patient verbalized understanding.” The initial plan was 
for a report to track the number of times the dot phrases were used to monitor TARCC usage at 
both primary care sites. However, based on feedback from the EHR specialists, the phrases were 
challenging to build and would not be built in time for the project. This occurred two weeks 
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before project implementation. Therefore, the dot phrases were available for providers to use; 
however, they were not monitored as a project outcome.  
Mid-implementation data collection. Eight weeks into the implementation period, a 
mid-implementation data collection tool was administered to 13 providers at both sites A and B 
(see Appendix H for Mid-Implementation Data Collection Tool). One provider at site A was on 
sabbatical starting the week after the educations session and returned the week the mid 
implementation tools were administered. This provider was not given a survey since he had not 
been at the clinic to use the TARCC framework. Outcomes were compared to preliminary survey 
results and guided PDSA cycles.  
Site A PDSA cycles. Five PDSA cycles were performed at site A throughout project 
implementation. The goal of each cycle was to improve provider knowledge and use of the 
TARCC framework. First, TARCC reminder cards were given out to all providers to place on 
their computer screens to help them remember to use the framework in practice (See Appendix K 
for TARCC Reminder Card and Appendix L for Site A Plan Do Study Act One). Next, the site 
champion and DNP student developed a checklist that included each component of the TARCC 
framework (See Appendix M for TARCC Checklist). Checklists were to be used with all women 
aged 18 to 50, which was compared to the number of women aged 18 to 50 seen by a provider 
each week (See Appendix N for Site A Plan Do Study Act Two). Outcomes were tracked 
weekly; however, no goal was set due to the lack of baseline and national benchmark.  
 The next PDSA cycle added weekly emails to providers that highlighted weekly checklist 
data and one teratogenic class of medication with references (See Appendix O for Site A Plan Do 
Study Act Three). During PDSA four, the DNP student and physician attempted to recruit an 
MA to help him identify which of his patients were eligible for a TARCC checklist (See 
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Appendix P for Site A Plan Do Study Act Four). Due to MA overburdening and understaffing, 
this strategy was not helpful and was not continued. At the end of implementation, the final 
PDSA included beginning to create a decision tree and best practice advisory for the electronic 
health record (See Appendix Q for Site A Plan Do Study Act Five).  
Site B PDSA cycles. The implementation at site B occurred one month after 
implementation started at site A; therefore, some changes were made at site B at the education 
session. For example, providers were given the TARCC reminder card (See Appendix K for 
TARCC Reminder Card) in their provider toolkit and were offered to use the TARCC checklists 
as was being done at site A. However, due to provider turnover and staff burnout, the providers 
opted not to add the checklists to their daily tasks. Three PDSA cycles were performed at site B 
throughout implementation. First, the site champion placed the TARCC framework and checklist 
into her well-woman physical exam template in the EHR and shared this idea with other 
providers (See Appendix R for Site B Plan Do Study Act One). The template was used during all 
female physicals and therefore ensured addressing teratogenic medication at all encounters. 
Next, the DNP student met with a pharmacist who worked at the clinic to help manage 
complicated chronic disease medications (See Appendix S for Site B Plan Do Study Act Two). 
The pharmacist helped set the plan to work on a decision tree and best practice advisory for the 
EHR (See Appendix T for Site B Plan Do Study Act Three). Additionally, site B providers were 
added to the weekly teratogenic information emails being sent to the site A providers at the 
recommendation of the site champion. Last, the site champion advocated for the consistent 
collection of last menstrual period and contraceptive use at all female provider visits.  
End of implementation. Providers were given a final data collection tool during weeks 
13 and 14 of project implementation (see Appendix H). Outcomes of the survey were compared 
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to mid implementation and preliminary surveys.  Additionally, DEDUCETM was used to extract 
reports on two long-term project outcomes. DEDUCETM  is a database that pulls electronic health 
record information from Epic indirectly. Reports were pulled by the Director of Nursing 
Research & Evidence-Based Practice one month after project implantation because data in 
DEDUCETM l  lag one month behind.  Outcomes data during project implementation were 
compared to outcomes one year before implementation.  The outcomes included the percentage 
of sexually active childbearing age women without contraception while on a teratogen and the 
percentage of women taking teratogenic medication. No percentage was set as a goal because 
there was no national benchmark and no baseline for TARCC usage.  
Plan Variation 
 The first variation was the stark difference in project implementation strategies between 
sites A and B. Site A was able to perform a daily task to track objective outcomes using the 
TARCC checklist. Site B was burnt out with provider and staff turnover as well as quality 
improvement saturation. Additionally, site A had a long-term relationship with the DNP student 
and had worked through the planning phase of the project. Site B, however, was added later in 
the project and therefore missed the planning and relationship building stages. Therefore, 
provider investment in the project was decreased at site B.  
 Additionally, working with a pharmacist at site B was an unexpected variation. The 
pharmacist was instrumental in building the best practice advisory and decision tree framework 
for the EHR. The pharmacist not only provided feedback on the framework but also helped 
coordinate feedback from clinical staff and information technology professionals. Likely, an 
interdisciplinary team with the pharmacist, two site champions, and other providers at the two 
clinics will serve as the pilot for a potential EHR advisory. This outcome was in line with 
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provider feedback on data collection tools and was, therefore, a positive outcome of the DNP 
project.  
Summary 
 Fourteen providers at two primary care clinics in an extensive university health system 
were recruited and engaged to participate in the DNP project. The practice medical directors 
helped plan meetings before implementation to discuss the project with all providers. At the 
meetings, providers expressed eagerness to improve medication prescription safety while 
addressing concerns about remembering to use TARCC.  
 Education sessions to discuss the TARCC framework were performed in Fall, 2019. The 
session described the best practice and current practice gaps at the clinic and nationally. Dot 
phrases were created to ensure easy documentation. Also, data collection tools were given to 
providers at three-time points in the project: post-education session, mid-implementation, and 
project completion. Multiple PDSA cycles were performed at each clinic to promote TARCC 
usage. Additionally, a new relationship was formed with a pharmacist that will help propel the 
sustainability of the project.  
Chapter Six:  Evaluation of the Practice Change Initiative 
Short-term, intermediate, and long-term outcomes were evaluated in the DNP project. 
Data collection tools were administered to participants at three time points throughout 
implementation to assess for change. Data from DEDUCETM was also gathered to evaluate long-
term outcomes. Participant demographics were gathered using the preliminary data collection 
tool. Last, figures were used to illustrate the improvement in project outcomes. 
Participant Demographics 
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           The participants of the DNP project were the primary care providers located at sites A and 
B. Demographic data about participants were collected using the preliminary data collection tool, 
which was completed by participants during the first week of implementation. Participants were 
asked to select their role and to record how many years of primary care experience they had. 
There were 14 participants across the two sites. The range of site A participants’ years’ 
experience was 1 to 22 with a mean of 11.3 (SD= 7.4 years). At site B, the range was 1 to 18 
years with a mean of 7.1 (SD=5.6 years).  
 At site A, a total of 1567 women aged 18 to 50 were seen by a provider over the last 10 
weeks of implementation. This was not monitored at site B. The number of women was tracked 
each week to compare to the number of TARCC checklists used at site A.  
Figure 1. The pie chart in Figure 1 illustrates the roles of the participants in the DNP 
project across sites A and B. The majority of participants were MDs, followed by NPs and PAs.  
Figure 1. DNP Project Participant Roles 
 
Figure 1. DNP Project participant roles. This figure illustrates the breakdown of roles for project 
participants at both sites A and B. 
Intended Outcomes 
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The DNP project focused on short-term outcomes such as provider competence in using 
the TARCC framework, frequency of use, and how likely providers were to use the framework 
over the next month. These short-term outcomes were evaluated using the preliminary, mid-
implementation, and end of implementation data collection tools. Changes in these short-term 
outcomes were assessed from beginning to the end of the project without a set goal due to a lack 
of national benchmarks and no previous use of the TARCC framework at either project site.  
Intermediate outcomes included provider ranking of the importance of placing the 
TARCC framework into the EHR, sharing the education with other primary care sites in the 
network, and how helpful providers felt TARCC was in improving the quality of their care. Each 
outcome was assessed using a 5-point scale with 5 being “most important” or “most helpful.” 
Providers ranked their perceived importance or helpfulness on the final data collection tool at the 
end of implementation. These outcomes represent possible future use of the TARCC framework 
and sustainability of the DNP Project based on provider perception.  
Two long term outcomes were assessed using EHR data that were pulled from 
DEDUCETM  by the Director of Nursing Research & Evidence-Based Practice. These outcomes 
directly related to patient outcomes that may have occurred with the increased use of the TARCC 
framework. The first was a reduction in the percentage of childbearing age women taking a 
teratogenic medication. The second was a reduction in the percentage of sexually active, 
childbearing age women without documented contraception while on a teratogenic medication.  
Findings 
At site A, TARCC checklist use was tracked over the last 10 weeks of implementation. A 
total of 1567 women aged 18 to 50 were seen by a provider over the 10 weeks. Each week the 
number of TARCC checklists used was compared with the number of women aged 18 to 50 seen 
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by a provider. The implementation percentage ranged from 8% to 29% with a mean of 16% 
(SD=6.9%) as shown in Figure 2. 
Both sites had an improvement in self-assessment of provider competency in using the 
TARCC framework throughout the project. For example, 86% of providers stated they were 
“very” or “extremely competent” in using the framework by the end of the project compared to 
43% and 57% at sites A and B, respectively, at the beginning of the project. At site A, 86% of 
providers stated that they used the framework more than seven times during implementation 
compared to only 14% of providers at site B. Last, both sites had an increase in the likelihood of 
use of the framework over the next month from beginning to end of implementation. At site A, 
86% of providers stated they would be “very” or “extremely” likely to use TARCC in the next 
month compared to 71% at the beginning of implementation. Similarly, at site B, 71% of 
providers stated they would be “very” or “extremely” likely to use TARCC in the next month 
compared to 57% at the beginning of implementation. 
A 5-point Likert scale was used to measure intermediate outcomes with 5 being 
“extremely important” or “extremely helpful.” Providers rated their perception of importance or 
helpfulness on each outcome. The analysis indicated a high rating for the importance of adding 
TARCC to the EHR with a mean rating of 4.6 (SD= 0.5) and 4.4 (SD= 0.8) at sites A and B, 
respectively. Similarly, both sites rated high importance of sharing the education session with 
other primary care sites with an average rating of 4.6 (SD= 0.5) on a 5-point scale. Finally, 
providers rated the usefulness of  the TARCC framework in improving their quality of care with  
providers at site A giving average rating of 3.7 (SD= 0.8) and at site B, an average of 3.9 (SD= 
0.4).  
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           Long term outcomes did not show a substantial change from baseline to end of 
implementation as shown in Table 1. Overall, there was a minimal decrease in the percent of 
women on a teratogen and a minimal increase in the percent of women without documented birth 
control.  
Figure 2. Weekly TARCC Use at Site A 
  
Figure 2. Weekly TARCC Use at Site A. 
Table 1. DNP Project Long Term Outcomes 
  
Summary 
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 Outcomes of the DNP project were gathered from data collection tools and DEDUCETM. 
Demographic data on the 14 participants illustrated that the majority were MDs, followed by 
NPs, and PAs. The range of years’ experience was vast, from one to 22. Short-term outcomes 
showed an improvement from the beginning of implementation to the end. Overall, there were 
increases in self-reported provider competency in using the TARCC framework as well as 
provider reported likelihood of using TARCC in the next month. TARCC was used more often at 
site A than at site B throughout implementation. At site A, TARCC use was tracked over the last 
ten weeks of implementation. Percent use varied week to week with a mean of 16% (SD=6.9%). 
Conversely, long-term outcomes did not show substantial change from baseline data one 
year before implementation compared to during implementation. Both sites A and B had a 2% 
decrease in the number of women actively using a teratogen. However, both sites had a small 
increase in the percent of women without documented birth control use despite being sexually 
active and on a teratogen.  
Chapter Seven: Implications for Nursing Practice 
The Essentials of Doctoral Education for Advanced Nursing Practice were created by the 
American Association of Colleges of Nursing (AACN) in 2006. The eight Essentials are 
qualities, skills, and competencies that all advanced practice nurses prepared at the doctoral level 
must obtain through their education and DNP project (AACN, 2006). The Essentials distinguish 
DNP graduates from PhD graduates by emphasizing the implementation of evidence-based 
practice rather than the generation of new knowledge (AACN, 2006). Each Essential will be 
defined as it relates to the DNP project. Additionally, implications from the DNP project will be 
explored as they relate to each Essential. Some implications have occurred throughout the 
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project, and some have implications after the completion of the project in future advanced 
nursing practice.  
Practice Implications 
Essential I: Scientific underpinnings for practice. The first essential highlights the 
importance of using multidisciplinary science and theory to improve patient outcomes and 
advanced nursing practice (AACN, 2006). Two primary care sites were found to have a problem 
with unsafe prescription of teratogenic medication. Data from one year before implementation 
showed that over 50% of sexually active childbearing age women prescribed a teratogenic 
medication did not have contraception documentation (D. Allen, personal communication, June 
27, 2019). During informal discussions with primary care providers, there were no frameworks 
or safety mechanisms in place when prescribing teratogenic medication (M. Fike, personal 
communication, June 30, 2019). Therefore, the DNP project utilized biophysical science about 
teratogenic medications, psychosocial science to explore unintended pregnancy, pregnancy risk, 
and contraceptive counseling, and implementation science to improve patient outcomes. A 
framework was researched to help providers increase the safety of teratogenic prescriptions 
(Shroff et al., 2017). A future implication to advance nursing science is sharing outcomes of the 
DNP project with the authors of the TARCC framework. This sharing will allow the authors to 
broaden their understanding of TARCC’s use in practice and may inform their current research. 
Also, the science behind safe contraceptive prescribing and teratogenic alternatives was not 
routinely used by all providers before the DNP project. To promote the scientific underpinning 
of practice, the DNP student will share the framework with all practices at the Practice Medical 
Director meeting, thus reaching more providers in the health system.  
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Essential II: Organization and systems leadership for quality improvement and 
systems thinking. Essential II highlights the importance of systems change, patient safety, 
ethical practice, and population health (AACN, 2006). The success of the DNP project has 
implications for improving patient safety by ensuring safe teratogenic medication management 
for childbearing age women. Organizational data from two primary care clinics in the same 
health system showed a need for change to enhance patient safety. However, the organizational 
culture and practice dictated how each site implemented the project. Therefore, the DNP student 
tailored quality improvement strategies to each organization and system to ensure success and 
sustainability, which is part of Essential II (AACN, 2006). For example, at site B, providers were 
burnt out from high rates of turnover and repeated quality improvement initiatives. Therefore, 
they did not want to add any tasks to provider visits. To implement the TARCC framework at 
site B, providers had the option to add the framework to their physical exam template, and the 
DNP student worked with the pharmacist to begin to develop a decision tree for the medical 
record. Opposingly, at site A, providers were not burnt out and had a low turnover rate. 
Therefore, providers were willing to implement a checklist at each female visit to increase the 
use of TARCC. Weekly data was pulled by the Health Center Administrator to track an objective 
measure of TARCC usage at site A which was not possible at site B.  
The DNP project also helped to manage the ethical dilemma between do no harm and the 
need to treat. Medications such as angiotensin-converting enzyme inhibitors, statins, and 
angiotensin blocking agents are first-line treatments in national guidelines for hypertension, 
hyperlipidemia, and diabetes. However, each one is a teratogen, and the provider has the 
responsibility to do no harm to the patient and a potential fetus during treatment. The use of the 
TARCC framework allowed the provider to weigh risks and benefits and provide patient 
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education and counseling. Therefore, the success of the project enhances ethical and safe patient 
care.  
Essential III: Clinical scholarship and analytical methods for EBP. Essential III 
focuses on the analysis of evidence to promote evidence-based care (AACN, 2006). A critical 
role of the DNP is the ability to discern whether research is valid, reliable, generalizable, and 
done with rigor before bringing the evidence into practice (AACN, 2006). Therefore, the DNP 
student used the skills of performing a literature review and evidence evaluation using the 
Melnyk Levels of Evidence to promote evidence-based care in two primary care sites (Melnyk & 
Fineout-Overholt, 2011). Evidence was used to support the problem that women in primary care 
are not likely to receive contraception with the prescription of a teratogen. Additionally, 
evidence supported the high risk and high rate of unintended pregnancy and the barriers that 
prevent providers from prescribing safely. The DNP student evaluated evidence-based 
interventions to increase teratogenic medication safety in primary care before the implementation 
of the TARCC framework (Shroff et al., 2017).  Last, the DNP student shared valuable articles 
with providers at each site over email every week. The articles deepened provider understanding 
of teratogens and the importance of the TARCC framework. Providers’ increased knowledge 
will carry on past the end of implementation, thus promoting clinical scholarship.  
Essential III also promotes the evaluation of improvement projects with an emphasis on 
dissemination and comparison to national benchmarks (AACN, 2006). The DNP project 
outcomes were in line with Healthy People 2020 goals and will allow the practices to improve 
patient outcomes for childbearing age women (USDHHS, n.d.). Project outcomes will be used to 
disseminate findings to all Practice Medical Directors in the network and to promote the 
inclusion of TARCC into organizational systems such as the electronic health record.  
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Essential IV: Information systems/technology and patient care technology for the 
improvement and transformation of healthcare. This Essential highlights the importance of 
information systems in providing quality care and in evaluating health outcomes (AACN, 2016). 
The most significant implication for practice for Essential IV was placing the TARCC 
framework into the EHR and provider workflow. It was difficult for providers to remember to 
use the TARCC checklist and reported on the final data collection tool a high rating for placing 
TARCC into the EHR. Without a consistent reminder to use the TARCC principles when they 
are prescribing a medication, it would not be possible to sustain the behavior change. Therefore, 
after implementation, the DNP student worked with the pharmacist and an interdisciplinary team 
to create a best practice advisory for the EHR. The DNP student will communicate the need to 
primary care management for TARCC in the medical record to ensure women are not exposed to 
teratogens when they are at risk for pregnancy. Additionally, the student will work to make the 
advisory trackable which will allow data to show improved patient outcomes.  
Essential V: Healthcare policy for advocacy in healthcare. DNP graduates must be 
able to evaluate existing policies and advocate for policy changes at all levels to enhance patient 
outcomes and reduce healthcare disparities (AACN, 2006). A policy already exists that outlines 
what should be included with all patient intakes before the provider visit. However, the policy is 
not being followed thoroughly. Therefore, not all patients have regular updates to their sexual 
activity, last menstrual period, and contraceptive use at site B. Advocacy for adherence and 
clarity of this policy is vital to providing safe prescribing of teratogenic medication. Therefore, 
the site champion brought attention to this policy during morning huddles and reported that more 
visits had included last menstrual period by the end of implementation (E. Stern, personal 
communication, November 20, 2019).  
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Additionally, the DNP student may advocate for changing the policy that dictates all 
women must have a physical within one year to receive birth control based on project outcomes. 
This is not something that occurred during the project. However, it may be necessary once 
outcomes are evaluated. Providers may prescribe other medications to control hypertension, 
cholesterol, or a seizure disorder; however, they may not be able to prescribe contraception with 
these medications. This policy may put the patient at a higher risk for unsafe teratogenic use. The 
DNP student will explore this policy with the practice medical directors to determine the key 
drivers and rationale for this policy. Working with stakeholders such as the medical directors, 
providers, and organizational leaders may help ensure this policy serves patients rather than 
reduce patient safety.  
Essential VI: Interprofessional collaboration for improving patient and population 
health outcomes. Essential VI calls for the DNP student to lead an interprofessional team 
through excellent communication and collaborative skills to implement quality improvement 
(AACN, 2006). To develop the project, the DNP student worked with a nurse practitioner, a 
Health Center Administrator, Director of Nursing Research, Associate Chief Medical Officer for 
Innovation and Improvement, and faculty members. The team worked together to gather baseline 
data and to create the scope, outcomes, and interventions during the planning stage. Throughout 
the project, the DNP student worked closely with a nurse practitioner and physician assistant as 
site champions to guide project implementation at their respective sites. They both helped create 
plan-do-study-act cycles with innovative interventions that fit their provider workflow. 
Additionally, a Health Center Administrator at site A was critical to collecting data to 
track program outcomes. A weekly report was generated by this administrator to identify the 
number of women aged 18 to 50 with provider encounters.  This data was used as the 
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denominator in a project outcome regarding the percent of women screened with the TARCC 
framework.  The DNP student also worked with a pharmacist at site B to start developing a best 
practice advisory and decision tree that could be placed into the electronic health record. After 
project implementation, the DNP student continued to work with the pharmacist, site champions, 
and other providers at the two clinics to receive feedback on the decision tree. Additionally, 
information technology professionals will be pulled in to provide feedback and build the 
framework into the health record if it is approved. The last interdisciplinary team members were 
the Practice Medical Directors that will be vital to sharing the project with practices across the 
network. At the end of implementation, the DNP student will present at the system-wide Practice 
Medical Director meeting, therefore allowing the TARCC framework to be shared across the 
health network.  
Essential VII: Clinical prevention and population health for improving the nation’s 
health. The DNP is trained to address population health through the lens of cultural diversity by 
using aggregate level data for health outcomes (AACN, 2006). An implication for practice for 
the DNP project was an improvement in certain Healthy People 2020 goals such as improvement 
of the intended pregnancy rate and a decrease in infant mortality and birth defect rates for 
women aged 18 to 50 (USDHHS, n.d.). During the project, the TARCC framework was applied 
to all women aged 18 to 50 at two primary care clinics, thus improving outcomes for a specific 
population, which is part of Triple Aim (IHI, 2019). The DNP project also improved the patient 
experience by enhancing shared decision making around medication risk/benefit and 
contraceptive use (IHI, 2019). 
Additionally, a reduction in healthcare costs through the prevention of birth defects, 
unintended pregnancy, and abortion is a vital aspect of increasing value in Triple Aim and could 
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be a potential long-term outcome of this project (IHI, 2019).  A further cultural implication for a 
future project would be to look at contraceptive use and teratogenic medication use by race, 
ethnicity, age, or income in each clinic. For example, unintended pregnancy rates are 
proportionally higher for low income Black and Hispanic women in the US (Finer & Zolna, 
2016; Morse et al., 2017). Therefore, if data from the clinics supported higher rates of teratogen 
use or lower contraceptive use for these populations, the student could target the TARCC 
framework for the most vulnerable aggregate, and the intervention could be tailored to be 
culturally appropriate for that particular group.  
Essential VIII: Advanced nursing practice. Essential VIII emphasizes the need for 
advanced clinical judgment and maintaining therapeutic relationships when implementing, 
evaluating, and providing evidence-based care (AACN, 2006). By working in two different sites, 
the DNP student had to form relationships with two site champions and two groups of providers. 
Advanced clinical judgment was needed to evaluate the workflow at each site and develop 
interventions to implement the TARCC framework effectively. The implication of using the 
TARCC framework and how to adjust medications accordingly is providing advanced clinical 
judgment. The provider must evaluate and weigh individual patient risks and preferences to 
determine the best medication and counseling needed for safe prescribing. Therefore, the DNP 
student advocated for a higher level of practice by all the providers in the project by 
implementing the framework.  
Summary 
 The eight DNP Essentials were imbedded into the DNP project and will carry on past 
implementation. Aspects of each essential were utilized during implementation to enhance 
patient safety, improve population health, and translate quality evidence-based care into practice. 
TERATOGENIC MEDICATION SAFETY                      69 
Including the TARCC framework into the medical record is an example of information systems 
being maximized to improve patient outcomes. Additionally, an interdisciplinary team and 
organizational buy-in will be critical to the inclusion of the framework into practice after 
implementation. During the project, the DNP student worked with two clinics with different 
organizational workflows and barriers to implementation. Therefore, becoming an 
interdisciplinary leader with excellent communication skills was a paramount and direct 
implication of the Essentials.  
Overall, the project mandates a higher level of advanced nursing practice by all providers 
involved. It encouraged providers to think through risk and benefit when treating patients for 
common chronic diseases. Providers were given the scientific underpinning for teratogenic 
medication and contraceptive management and should continue to use this knowledge after the 
DNP project. The project also highlighted the importance of the ethical dilemma of doing no 
harm and the need to treat. By implementing the TARCC framework, providers practiced a 
higher level of care that increased the safety of teratogenic medication prescriptions.  
Chapter Eight: Final Conclusions 
The DNP project produced an increase in provider awareness of teratogenic medication 
and safe prescribing. The project highlighted a need for the systematic use of the TARCC 
framework to reduce the risk of teratogenic effects. Based on the findings from the project, it was 
recommended to place a best practice advisory into the EHR to prompt consistent framework 
use.  It was also recommended to share the project education session, TARCC framework, and 
EHR advisory with other practices in the network.  
Significance of Findings  
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 At the end of the DNP project, providers reported a higher level of confidence in using 
the TARCC framework and a higher likelihood of use in the next month. Providers at both sites 
were creative in how they chose to merge TARCC with their current practice. Some providers 
decided to put the TARCC framework and checklist into their EHR templates for well-women 
physical exams. This would allow providers to discuss contraception and medication 
reconciliation during a visit that typically allows for more time. Another provider used the 
TARCC checklist each morning while looking over her schedule and flagged any patients that 
were on teratogenic medications without birth control. She was able to use the checklist with 
those patients to improve the safety of prescribing. Therefore, the TARCC framework was 
flexible enough for providers to merge with their current practice in different ways. This 
flexibility made the framework applicable to providers in different settings with different 
workflows. 
 Additionally, four providers, in particular, were impacted by the use of the framework 
during the project implementation. A PA at site B had a patient who was going through infertility 
insemination treatments for over one year while on lisinopril. Lisinopril is in the class of ACE 
inhibitors, which is a teratogenic class. The infertility specialists had not taken her off the 
medication despite several failed insemination attempts. The PA used the TARCC framework 
and stopped the lisinopril and started her on a safer medication. Therefore, the provider reduced 
the risk of teratogenic effects on future pregnancy and stated that she was much more aware of 
teratogenic medication after the DNP project (E. Stern, personal communication, January 4, 
2020). An FNP at site A was also empowered to discuss the risk of starting a teratogenic 
antibiotic to prevent acne. Her patient refused all forms of birth control and had a history of 
several abortions. The FNP reported she knew from the project education session to refuse to 
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prescribe the teratogenic medication without a plan for contraception (V. Dalalau, personal 
communication, October 7, 2019). A physician at site A also reported she used the framework 
many times and appreciated how easy it was to use (M. Fike, personal communication, 
September 12, 2019). Last, another FNP at site A prescribed phentermine and topiramate, which 
were both teratogenic mediations. She realized she had not discussed pregnancy risk or 
contraception with the patient until she saw the TARCC reminder card on her desk (M. Fike, 
personal communication, October 16, 2019). She promptly had the MA bring the patient back to 
the exam room to discuss pregnancy risk and contraceptive counseling. This is also an example 
of how providers used awareness of teratogenic medication and applied it to classes of 
medications not addressed during the education session.  
 The patient stories illustrated how impactful the TARCC framework and knowledge of 
safe prescribing were for providers and patients. The education session increased provider 
awareness when prescribing teratogenic medications. The framework also helped providers do a 
more thorough medication reconciliation to ensure women were not on teratogens or had 
contraption if they were. Based on the final data collection tool, providers across the two sites 
used the TARCC framework at least 86 times during implementation. At site A, 249 TARCC 
checklists were used over ten weeks. Before the project, the TARCC framework was not in use, 
and providers did not routinely or systematically assess the safety of medication for childbearing 
age women. Therefore, a 16% average use of the TARCC checklist at site A implied 
improvement.  
Project Strengths and Weaknesses 
 The strengths of the project included the support of site champions, the flexibility of the 
TARCC framework, and the low cost of the project. The site champions were instrumental in 
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reminding providers to use the framework and in brainstorming PDSA cycles to improve the 
project. The site champions ensured all providers participated in the three data collection surveys 
and attended the education session. The site champion at site B came up with the idea of adding 
the framework to physical exam templates and shared this with other providers. She also 
encouraged the DNP student to meet with a pharmacist who became part of the sustainability of 
the project by helping to create a best practice advisory for the EHR. The flexibility of the 
framework allowed providers to implement it into their workflow. It helped to change the 
provider’s thought process when doing medication reconciliation and prescribing medication. 
Therefore, the framework may have impacted more patients than is evidenced by the number of 
checklists collected. Last, the cost of the project was around $300, which was well under the 
potential savings of preventing one birth defect or one abortion.  
          The weaknesses of the project included a lack of MA participation and electronic health 
record access. The MAs at both sites were overburdened and short-staffed. It is possible that with 
MA support, the TARCC framework would have been used more often. During triage, the MAs 
do medication reconciliation, which could have been an opportunity to flag teratogenic 
medication for providers before the visit. MAs could have also flagged women aged 18-50 and 
attached a TARCC checklist to prompt provider use. However, after trying this with one provider 
and MA, it was determined that the MAs did not have time for this additional task. Also, the 
DNP student was not able to pull reports or flag patients in real-time to help providers target 
their use of TARCC. A chart review would have helped find patients being seen who were on a 
teratogenic medication without documented contraception. Last, there was no reminder in the 
electronic health record to use the TARCC framework, therefore the project relied solely on 
paper checklists that were hard to incorporate into everyday workflow.  
TERATOGENIC MEDICATION SAFETY                      73 
Project Limitations 
 The limitations of the project were the short duration of implementation, confounding 
factors affecting long-term outcomes, and decreased involvement of site B during the planning 
phase. The project implementation at site A was three months, and at site B for about two 
months. It was difficult to change provider behavior in a short time. Additionally, the long-term 
outcomes were difficult to assess for change due to the short duration of the project. The long-
term outcomes also relied on data entry for current sexual activity, birth control use, and 
medication reconciliation. The DNP student did not have access to the EHR or involve the MAs. 
Therefore, it was difficult to ensure data entry was timely, accurate, and thorough. Thus, the lack 
of change in long-term outcomes could be related to those confounding factors. Last, the long-
term outcomes did not fully reflect whether TARCC was being used. For example, if providers 
used the framework and provided counseling, the woman may not have chosen to use birth 
control. Therefore, even though providers changed their practice, it was not reflected in the 
percent of women using birth control while on a teratogen.  
 Site B was not involved in the initial planning phase of the DNP project. The site was 
added after a meeting with senior management at the end of the planning phase. Additionally, the 
DNP student had no previous relationship with site B providers or managers. As a result, site B 
providers were not willing to incorporate the TARCC checklists and were not as responsive to 
the weekly teratogen emails. Site B also had competing quality improvement project initiatives 
while also being short-staffed. Overall, providers at site B did not have as much time to 
incorporate TARCC into their practice or participate in the development of PDSA cycles.  
Project Benefits 
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The project benefited the providers and organization because it illuminated a gap in safe 
practice. Providers realized they were not routinely evaluating the risk of teratogenic medication 
for childbearing age women. The TARCC framework helped providers change their thought 
process when prescribing medication and when performing medication reconciliation. 
Additionally, the education session gave providers tools to use when performing contraceptive 
counseling and in determining safer alternative medications. Even though the session focused on 
six commonly used classes of teratogenic medications, providers extended their learning to other 
drugs such as phentermine, topiramate, and doxycycline. Therefore, the most significant benefit 
was increased provider awareness of teratogenic medications and how to prescribe them safely. 
The providers felt the education session and framework were important enough to share with 
other primary care sites in the network. Also, providers felt the TARCC framework should be 
incorporated into the EHR despite the burden best practice advisories often have on provider 
workload. An extra stop in the EHR when prescribing medication would take more provider 
time. However, providers felt strongly that patient safety was at stake if the TARCC decision 
tree was not used as a regular part of their workflow.  Also, the potential cost saving is 
considerable. Preventing the need for an abortion could save $450-$5000. Additionally, the 
prevention of one severe birth defect could save $78,000 in hospital costs in one year.  
Practice Recommendations 
 The most significant recommendation for organizational change was to incorporate a best 
practice advisory into the electronic health record. Providers felt the TARCC framework was 
useful to improve medication prescription safety; however, it was difficult to remember to 
implement it routinely. As a result, the DNP student will work with an interdisciplinary team, 
including providers, information technology, and a pharmacist, to create the advisory. When a 
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teratogenic medication is prescribed for a woman of childbearing age, the EHR will trigger an 
advisory message. The advisory will alert the provider of the teratogenicity of the medication 
and recommend that action be taken to ensure safe prescribing. The provider will then be able to 
choose an appropriate response such as “no pregnancy risk,” “contraceptive/pregnancy risk 
counseling provided,” “contraception prescribed,” or “alternative medication chosen.” The 
advisory will imbed the TARCC concepts into the workflow of all providers in the network. 
Also, the education session and advisory framework will be shared with other practices in the 
system via a voiceover PowerPoint or live session.  
 The concepts of the TARCC framework can be applied to any setting where women of 
childbearing age receive care. However, it requires systematic integration into the practice’s 
workflow. The TARCC checklist was an easy way for providers to incorporate safe prescribing 
into their practice. Yet, it was challenging to remember to use it with all patients. The TARCC 
reminder cards for provider computers helped some providers remember to use the framework. 
However, it was not consistent. Therefore, integration into the workflow or the EHR would be 
recommended for future project replication. For example, MAs can flag patients during triage 
that are on teratogenic medication without birth control. Another option would be a report that 
shows providers which of their patients use teratogenic medications without birth control. 
Therefore, the concepts of the DNP project can be used in other settings to improve medication 
safety; however, the framework must be integrated into that office’s workflow. Without better 
integration, providers forget to incorporate TARCC components into their practice routinely.  
Final Summary 
          The DNP project was successful in increasing provider awareness of teratogenic 
medication safety for childbearing age women in primary care. Providers began to change their 
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practice by incorporating TARCC principles into their workflow. Throughout the project, 
providers reported increased competence in using the framework and increased likelihood of 
using the framework in the future. Patient stories illustrated how impactful the DNP project was 
on provider prescribing practices. Additionally, the providers felt the education session should be 
shared with other primary care sites in the network and that TARCC should be embedded in the 
EHR. Based on provider feedback, a best practice advisory will be developed for the EHR. The 
advisory will alert providers to teratogenic medications when they are prescribed and prompt the 
provider to take action to increase the safety of prescribing.  
 There were also barriers to success, including the short duration of the project, lack of 
site B involvement in planning, and lack of access to MAs and the EHR. It was difficult to 
change provider behavior without the help of MAs, personalized EHR reports, and a short 
project. Additionally, without TARCC in the EHR, paper checklists were challenging to 
remember to use regularly. Thus, there was a 16% average TARCC checklist use at site A. 
However, patient stories and provider feedback on data collection tools illustrated there was 
evidence of practice change and an increase in overall awareness of teratogenic medication 
safety.  
 The DNP project will be sustained by sharing the education session and advisory 
framework with providers across the primary care network. Additionally, the best practice 
advisory will be developed in conjunction with an interdisciplinary team that will be 
implemented for all primary care sites. Overall the TARCC framework, checklist, and education 
session materials could be used at other facilities where childbearing age women are prescribed 
medications. However, an essential aspect of replication would be incorporating the framework 
into provider workflow systematically to ensure a higher rate of TARCC usage.  
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Appendix E 
DNP Project Budget 
 
 
Line Item Quantity Unit Cost Total 
    
Educational Seminar    
    
Food    
Case of Bottled Water 2 $2.99 $5.98 
Soda 6 $2.00 $12.00 
Set of Napkins 2 $1.00 $2.00 
Set of Plates 2 $1.00 $2.00 
Set of Cups 2 $1.00 $2.00 
Food 2 $50.00 $100.00 
    
 
   
Materials    
Packet of Handouts 20 $3.00 $60.00 
Box of Pens 2 $5.00 $10.00 
Folders 20 $2.00 $40.00 
Copies Education Survey 40 $0.04 $1.60 
 
   
Supplies    
Copies of Mid Project Survey 20 $0.04 $0.80 
Copies of Post Implementation Survey  40 $0.04 $1.60 
TARCC Baby Computer Slider 15 $3.00 $45.00 
Snacks Throughout Project 1 $50.00 $50.00 
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Appendix H 
DNP Project Data Collection Tools 
 
Teratogenic Medication Safety in Primary Care 
Preliminary Data Collection Tool 
 
 
1. Circle your role in the clinic: MD, NP, PA 
 
 
2. Years of primary care experience: 
 
3. Circle how competent you feel in your ability to use the TARCC framework: 
 
1 Not at all competent 
2 A little competent 
3 Somewhat competent 
4 Very competent 
5 Extremely competent 
 
 
4. Circle how competent you feel in your ability to provide effective contraceptive 
counseling: 
 
1 Not at all competent 
2 A little competent 
3 Somewhat competent 
4 Very competent 
5 Extremely competent 
 
 









6. What would make prescribing lisinopril to a 41-year-old female safe? Select all that 
apply: 
 
 Switch it to a calcium channel blocker or beta blocker 
 Switch it to an angiotensin-converting enzyme inhibitor 
 Switch it to an angiotensin-receptor blocker 
 Ensure she is on contraception 
 Discuss pregnancy risk with the patient 
 Nothing, this is a safe medication for this patient 
 
7. How likely are you to use the TARCC framework over the next month? 
 
1 Not likely 
2 Slightly likely 
3 Somewhat likely 
4 Very likely 
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Teratogenic Medication Safety in Primary Care 
Mid-Implementation Data Collection Tool 
 






10 or more 
 
2. How likely are you to use the TARCC framework in the next 1 month? 
1 Not likely 
2 Slightly likely 
3 Somewhat likely 
4 Very likely 
5 Extremely likely 
 
 









4. Circle how competent you feel in your ability to use the TARCC framework: 
 
1 Not at all competent 
2 A little competent 
3 Somewhat competent 
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4 Very competent 
5 Extremely competent 
 




Teratogenic Medication Safety in Primary Care 
Final Data Collection Tool 
 
 
1. Circle how competent you feel in your ability to use the TARCC framework: 
 
1 Not at all competent 
2 A little competent 
3 Somewhat competent 
4 Very competent 
5 Extremely competent 
 






10 or more 
 






4. How helpful do you feel the TARCC framework has been in improving the quality of 
your care? 
 
1 Not at all helpful 
2 A little helpful 
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3 Somewhat helpful 
4 Very helpful 
5 Extremely helpful 
 
 
5. How helpful do you feel it would be to have the TARCC framework be an automatic 
reminder in Epic if you prescribe a teratogenic medication? 
 
1 Not at all helpful 
2 A little helpful 
3 Somewhat helpful 
4 Very helpful 
5 Extremely helpful 
 
6. How important is it that the education session and TARCC framework be shared with 
other primary care sites in the network? 
 
1 Not at all important 
2 A little important 
3 Somewhat important 
4 Very important 
5 Extremely important 
 
7. How likely are you to use the TARCC framework over the next month? 
 
1 Not likely 
2 Slightly likely 
3 Somewhat likely 
4 Very likely 
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Appendix I 
Site A Education Session PowerPoint Slides  
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Appendix J 
Site B Education Session PowerPoint Slides   
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Appendix K 
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Appendix L 
Site A Plan Do Study Act One 
Objective: Increase provider knowledge and use of the TARCC framework in a primary care 
practice. 
1. Plan: Implement a 1-hour provider education session about the TARCC framework, 
including background information about the problem of teratogenic medication in 
primary care.  
a. Prediction: Providers will be able to use the TARCC framework in practice after 
the education session and be able to answer knowledge uptake questions correctly 
on the preliminary data collection tool.  
b. Who, what, where, when: Seven primary care providers in a primary care 
practice will participate in the 1-hour education session on August 22, 2019. 
Providers will receive a toolkit with session materials, including tools to teach 
contraceptive counseling.  
c. Plan to collect data: Each provider will complete a preliminary data collection 
tool immediately after the education session. The tool contains perceived 
competency questions and knowledge uptake questions about TARCC usage.  
2. Do: The education session was cut short to 25-30 minutes. Six providers attended the 
entire session, and one provider attended for the last 10 minutes. The session was more of 
a discussion in which providers applied the framework to their practice. Due to the 
shortened session, the preliminary data collection tool was not collected immediately 
after the meeting but rather the week after. Ultimately, seven data collection tools were 
collected and completed. 
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3. Study: The average rating for competency in using the TARCC framework was 3.6 on 5-
point scale. Only 43% rated themselves as “Very or Extremely Competent” in using 
TARCC. The average rating for competency in performing effective contraceptive 
counseling was 4.1 on 5-point scale. 86% rated themselves as “Very or Extremely 
Competent” in contraceptive counseling. 71% got the TARCC acronym correct, and 71% 
got the case scenario right. 71% stated they were “Very or Extremely Likely” to use the 
TARCC framework in the next month with an average rating of 3.6 on a 5-point scale. 
 
Less than half feel competent using the TARCC framework, and less than 80% were 
correct on the knowledge uptake survey. During informal conversations, providers stated 
it was hard to remember to use TARCC and that they needed better reminders.  Also, at 
this time, it is not possible to track the exact number of times providers use TARCC in 
practice.  
 
4. Act: Providers stated they needed more readily available reminders about the TARCC 
framework to make it more likely to use in practice. Providers will be given TARCC 
reminder laminated cards to put on their computers to aid in reminding them what the 
acronym stands for and to use it in practice when prescribing medication. Also, plan to 
repeat the TARCC, meaning knowledge uptake question on the mid-implementation tool 
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Appendix N 
Site A Plan Do Study Act Two  
Objective: Increase provider knowledge and use of the TARCC framework in a primary care 
practice. 
 
1. Plan: Providers stated they needed more readily available reminders about the TARCC 
framework to make it more likely to use in practice. Providers will be given TARCC 
reminder laminated cards to put on their computers to aid in reminding them what the 
acronym stands for and to use it in practice when prescribing medication.  
a. Prediction: Providers will be more likely to use the TARCC in practice and will 
be able to reiterate the TARCC acronym correctly.   
b. Who, what, where, when: Seven primary care providers in a primary care 
practice will be given a laminated card with the TARCC acronym spelled out 
along with the two dot phrases they can use to chart its use in the electronic health 
record. The card will be given out along with snacks during provider lunch 
breaks.  
c. Plan to collect data: Informal discussions with providers will determine if this 
aided in using the TARCC framework and in understanding what the framework 
means. 
2. Do: Six providers were given a baggie with snacks that were attached to the TARCC 
reminder card and Velcro stick pad. One provider is out on leave for six weeks. It was 
suggested to put the card on their computers on the bottom left corner since that is where 
they enter medications into the medical record. During discussions with providers, they 
stated it would be helpful to have a more systematic way to use the TARCC framework 
TERATOGENIC MEDICATION SAFETY                      132 
to make it a more ingrained process in their care. One provider voiced a concern that she 
sees many patients over 65 years in which this is not applicable.   
3. Study: After one week of using the reminder cards, one provider stated she had used the 
framework three times and was appreciative of the information. Another provider stated 
she used it two to three times last week but had a hard time remembering to use it more 
consistently. The site champion said it would be good to have reminders in the rooms 
with patients so they can use the framework when they are actively looking at patient 
medications. Another provider wanted a reminder to use while doing pre-work in the 
morning so she could identify which patients would benefit from TARCC usage. It would 
also be helpful to have a way to objectively track the number of times TARCC is used. 
4. Act: A checklist with the TARCC decision tree will be created on small bright colored 
sheets and placed in exam rooms. Copies of the checklist will also be given to providers 
to use at their desks during pre-work. The checklist will also include women aged 18-50, 
so providers know for whom the acronym applies. Providers can check off the 
appropriate box ideally for all women they see aged 18-50. The providers will then place 
the checklists in designated boxes for collection by the DNP student each week. The 
number of checklists collected will be compared to the number of women seen in clinic 
every one to two weeks who are 18-50 years old. This denominator will be collected by 
the Health Center Administrator and given to the student in a de-identified report.  This 
will aid in tracking TARCC usage while also increasing provider reminders to use the 
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Appendix O 
Site A Plan Do Study Act Three  
Objective: Increase provider knowledge and use of the TARCC framework in a primary care 
practice. 
 
1. Plan: A checklist with the TARCC decision tree will be created on small bright colored 
sheets and placed in exam rooms. Copies of the checklist will also be given to providers 
to use at their desks during pre-work. The checklist will also include women aged 18-50, 
so providers know for whom the acronym applies. Providers can check off the 
appropriate box ideally for all women they see aged 18-50. The providers will then place 
the checklists in designated boxes for collection by the DNP student each week.  
a. Prediction: The checklist will aid in tracking TARCC usage while also increasing 
provider reminders to use the TARCC framework in the exam room with patients. 
b. Who, what, where, when:  Checklists will be given to all primary care providers 
working at the site and drop boxes will be placed at all provider desks. The 
checklists will be started on Monday, September 23, 2019 and the first data pull 
will be on Monday September 30, 2019. 
c. Plan to collect data: The number of checklists collected will be compared to the 
number of women aged 18 to 50 who were seen in the clinic every week. This 
denominator will be collected by the Health Center Administrator and given to the 
student in a de-identified report each Monday for the week before. The DNP 
student will empty the boxes 1-2 times weekly to keep a count of the forms. 
Informal feedback from providers will also be used to determine the success of 
the PDSA. 
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2. Do: On Monday, September 23, 2019, six providers were given checklists. The seventh 
provider is still out on leave. Five of the providers wanted their checklists placed in their 
exam rooms near the computer and pen holder. One provider wanted hers in her pocket to 
use wherever she is. The last provider wanted them at her desk to use during pre-work 
each morning. Each provider has a dropbox at their desk or in their office. A total of 300 
copies of the checklists were placed throughout the clinic. The DNP student met with 
each provider for a few minutes to discuss the checklist and answer questions.  
3. Study: A total of 41 checklists were completed for patients in the first week of its use. 
Providers stated that the checklist made it much easier for them to remember to use the 
framework. A total of 178 women aged 18 to 50 were seen in the clinic the week of 
September 23rd. Therefore 23 % of women aged 18-50 received the screening.  
4. Act: To further increase the use of the TARCC checklist, a weekly Monday morning 
email will go out, highlighting one teratogenic medication class or article. The email will 
go to all providers, and the site champion will highlight it at huddle. This will begin 
Monday October 7th.  I also plan to put balloons on the checklist drop boxes and provide 
more snacks to providers to remind them to use the checklists. This will be done with the 
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Appendix P 
Site A Plan Do Study Act Four  
Objective: Increase provider knowledge and use of the TARCC framework in a primary care 
practice. 
 
1. Plan: To further increase the use of the TARCC checklist, a weekly Monday morning 
email will go out, highlighting one teratogenic medication class or article. The email will 
go to all providers, and the site champion will highlight it at the huddle. This will begin 
Monday, October 7th. I also plan to put balloons on the checklist drop boxes and provide 
more snacks to providers to remind them to use the checklists. This will be done with the 
mid-implementation survey the week of 10/14. 
a. Prediction: The weekly email will give providers a weekly reminder about using 
the checklist and feedback on progress. It will also increase provider knowledge 
of teratogenic medication to use in practice.  
b. Who, what, where, when:  Weekly email will go out to seven primary care 
providers and the Health Center Administrator. The email will include the 
previous week’s rate of TARCC usage and highlight one class of teratogenic 
medication. Emails start Monday, October 7th. The seven providers will also be 
given a mid-implementation survey the week of 10/14.  
c. Plan to collect data: Continue to collect the percentage of women aged 18-50 
who receive TARCC screening each week. We will also be collecting data on the 
mid-implementation survey.  
2. Do: On Monday, October 7th, the first email went to all providers, which highlighted 23% 
TARCC usage and ACE inhibitors. The following week an email was sent that reported a 
drop in TARCC usage to 13% and highlighted statins. The third email was sent on 10/21, 
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highlighting a slight increase in TARCC usage (14%) and highlighted benzos. The mid 
implementation survey was completed 10/16 and 10/17. Two providers completed the 
surveys the week of 10/21 because they were out of the office the end of the week before. 
Six providers completed the mid implementation survey compared to seven on the 
preliminary survey because one provider has been out on sabbatical since the education 
session and has just gotten back. Snacks and small balloons were attached to the drop 
boxes to further remind providers about using the survey.  
3. Study: There was a decrease in the percentage of women receiving a TARCC screening 
in week 2 (13%) compared to week 1 (23%). This may be because the first week, it was 
new, and there was a big push to complete the checklists. The weekly provider emails 
started on 10/7, and that week we saw 14% of women receive the TARCC checklist. 
Therefore, it is possible that the emails are helping increase provider awareness. The site 
champion felt the emails were helpful, and we agree they should be continued. One 
provider stated he is having trouble remembering to use the framework and would like 
his CMA involved.  
Based on the mid-implementation surveys, 50% of providers reported they are 
very or extremely comfortable using TARCC compared to 43% on the preliminary 
survey. Also, 83% wrote the TARCC acronym correctly vs. 71% on the preliminary. I 
have had a couple of informal discussions with providers about how the TARCC 
framework helped them have a good discussion with a patient and altered their plan of 
care. 83% of providers reported they had used the TARCC framework seven or more 
times since the education session, and 40% reported they had used it ten or more times. 
The average likelihood that providers will use TARCC in the next month increased to 4.0 
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from 3.6. However, only 67% of providers stated they are very or extremely likely to use 
it over the next month compared to 71% in the preliminary survey. Overall there has been 
an improvement in TARCC usage since the preliminary survey. Providers want to see 
this incorporated into the medical record and have CMAs help in administering the 
TARCC framework.  
4. Act: We plan to pilot the use of a CMA to help a provider remember to use the 
framework. She will attach a checklist to every face sheet for a woman aged 18-50. This 
will prompt the provider to fill out the checklist during the visit. If this is successful for 
the provider, other providers will be offered the same option. Providers can then talk to 
their CMAs about the process, and the DNP student will support the new plan. Also, we 
will share Site B’s idea of placing the TARCC checklist and acronym in Epic as part of 
the well-woman exam template. Last, we will continue the weekly provider emails and 
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Appendix Q 
Site A Plan Do Study Act Five 
Objective: Increase provider knowledge and use of the TARCC framework in a primary care 
practice. 
 
1. Plan: We plan to pilot the use of a CMA to help a provider remember to use the 
framework. She will attach a checklist to every face sheet for a woman aged 18-50. This 
will prompt the provider to fill out the checklist during the visit. If this is successful for 
the provider, other providers will be offered the same option. Providers can then talk to 
their CMAs about the process, and the DNP student will support the new plan. Also, we 
will share Site B’s idea of placing the TARCC checklist and acronym in Epic as part of 
the well-woman exam template. Last, we will continue the weekly provider emails and 
start a countdown to project completion. 
a. Prediction:  This will increase the provider’s ability to use TARCC with all of his 
female patients aged 18 to 50. 
b. Who, what, where, when:  One provider will try this with his one CMA. 
Discussed with provider and CMA week of 10/14.  
c. Plan to collect data: Plan to continue collecting weekly TARCC checklist usage 
data.  
2. Do: Discussed with provider and CMA the checklist process on 10/16. Gave checklists to 
CMA and provider.  
3. Study: Provider gave feedback that his CMA has not had time to help him. She is busy 
doing her other tasks and is already struggling to do those. He has started looking at his 
patient load each morning and trying to complete one checklist for every female aged 18-
50. He did notice that he only has one or two patients in that category each day. The week 
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of 10/14, we had the highest percentage of TARCC checklists used at 29%. This is likely 
related to the midterm survey and reminding providers about the checklist. The week of 
10/21 usage was back down to 16%, and the week of 10/28 down to 12%. The week of 
10/28 there were several providers out of the office, and they were short CMAs. This 
could be related to the decline. The final semester survey is happening the week of 11/12. 
The highest ratings on the survey were placing a reminder in Epic and sharing TARCC 
with other primary care offices. 83% stated they are very or extremely competent in using 
TARCC compared to 43% at the beginning of the project. 4.17 rating for likelihood of 
using TARCC in the next month compared to 3.6 at the beginning of the project.  
4. Act: Based on survey results, the DNP student will contact Lisa Nadler regarding 
encounter specialist templates and adding TARCC. Also, the student will continue to 
work on the decision tree/BPA for Epic. At this point, it is clear a systematic reminder in 
Epic is needed to promote use of TARCC. Also, this project will be shared with the 
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Appendix R 
Site B Plan Do Study Act One  
Objective: Increase provider knowledge and use of the TARCC framework in a primary care 
practice. 
 
1. Plan: Implement a 1-hour provider education session about the TARCC framework, 
including background information about the problem of teratogenic medication in 
primary care. Include TARCC reminder card in provider toolkit.  
a. Prediction: Providers will be able to use the TARCC framework in practice after 
the education session and be able to answer knowledge uptake questions correctly 
on the preliminary data collection tool.  
b. Who, what, where, when: Seven primary care providers in a primary care 
practice will participate in the 1-hour education session on September 24, 2019. 
Providers will receive a toolkit with session materials, including tools to teach 
contraceptive counseling and a TARCC reminder card.  
c. Plan to collect data: Each provider will complete a preliminary data collection 
tool immediately after the education session. The tool contains perceived 
competency questions and knowledge uptake questions about TARCC usage.  
2. Do: The education session was attended in full by seven primary care providers on 
September 24, 2019. The session was 50 minutes in total. All seven providers completed 
the preliminary data collection tool immediately after the education session.  
3. Study: The average rating for competency in using the TARCC framework was 3.4 on a 
5-point scale. Only 57% rated themselves as “Very or Extremely Competent” in using 
TARCC. The average rating for competency in performing effective contraceptive 
counseling was 3.9 on 5-point scale. 86% rated themselves as “Very or Extremely 
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Competent” in contraceptive counseling. 100% got the TARCC acronym correct, and 
86% got the case scenario right. 57% stated they were “Very or Extremely Likely” to use 
the TARCC framework in the next month with an average rating of 3.7 on a 5-point 
scale. Based on this data, improvement is needed to increase the likelihood that providers 
will use the framework and their comfort in using it.  
4. Act: The site champion suggested that providers create a phrase with the TARCC 
framework to put into the female physical exam template in Epic. This will increase the 
likelihood that providers will remember to use the framework during well-woman exams. 
The site champion stated that these visits are more likely to allow for time to discuss 
medications and birth control. Also, birth control can only be prescribed or refilled if a 
woman has had a physical within the past year. This suggestion will go out to providers 












TERATOGENIC MEDICATION SAFETY                      142 
Appendix S 
Site B Plan Do Study Act Two 
Objective: Increase provider knowledge and use of the TARCC framework in a primary care  
practice. 
 
1. Plan: The site champion suggested that providers create a phrase with the TARCC 
framework to put into the female physical exam template in Epic. This will increase the 
likelihood that providers will remember to use the framework during well-woman exams. 
The site champion stated that these visits are more likely to allow for time to discuss 
medications and birth control. Also, birth control can only be prescribed or refilled if a 
woman has had a physical within the past year. This suggestion will go out to providers 
in an email on Thursday and will be discussed at huddle by the site champion on Monday 
morning. 
a. Prediction:  Providers will incorporate TARCC into their well-women templates 
and become more competent in using the TARCC framework. 
b. Who, what, where, when: Email will be sent to all seven providers with site 
champion’s idea and a screenshot of how she incorporated it into her template.  
c. Plan to collect data: Mid implementation survey to be administered week of 
10/14 to all seven providers.  
2. Do: Email was sent to providers on October 3rd with a follow-up email with the 
screenshot on Oct 15th. Mid implementation surveys were handed out on 10/15. Surveys 
were collected and returned by site champion on 10/18 except for one provider who was 
out on vacation for the week. The final survey was collected on 10/21.   
3. Study: Providers reported a slightly higher rating of TARCC competency from 
preliminary to midterm (3.4 to 3.7). However, only 57% of providers reported they were 
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very or extremely competent at using TARCC, which is the same percentage from the 
preliminary survey. The providers had an average of 3.0 for the likelihood of using the 
TARCC framework in the next month, which is lower than the 3.7 average on the 
preliminary survey. After a discussion with the site champion, it is likely that with 
competing demands, staff turnover, and lack of computerized reminders, providers are 
unlikely to use TARCC.  
4. Act: To promote reminders about TARCC and increase provider awareness, the DNP 
student will send the providers a weekly email highlighting a teratogenic class. Also, the 
student will reach out to the pharmacist, who is in the clinic once per week. He works 
with patients with chronic diseases and often makes recommendations for medications 
for hypertension, cholesterol, and diabetes. Therefore, several classes of teratogenic 
medications are often recommended to providers. The DNP student will reach out to him 
to see what strategies he uses to ensure safe teratogen prescribing and offer the TARCC 
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Appendix T 
Site B Plan Do Study Act Three 
Objective: Increase provider knowledge and use of the TARCC framework in a primary care 
practice. 
 
1. Plan: To promote reminders about TARCC and increase provider awareness, the DNP 
student will send the providers a weekly email highlighting a teratogenic class. Also, the 
student will reach out to the pharmacist, who is in the clinic once per week. He works 
with patients with chronic diseases and often makes recommendations for medications 
for hypertension, cholesterol, and diabetes. Therefore, several classes of teratogenic 
medications are often recommended to providers. The DNP student will reach out to him 
to see what strategies he uses to ensure safe teratogen prescribing and offer the TARCC 
framework to him as well. 
a. Prediction:  Weekly provider emails will remind them to use TARCC in their 
practice. Ideas from the pharmacist will be used to improve outcomes in the 
project, as well.  
b. Who, what, where, when: Meeting with pharmacist set for 11/1. Weekly emails 
to providers started on 10/20. 
c. Plan to collect data: Meeting with site champion for feedback. Final data 
collection tool planned for 11/19.   
2. Do: Met with the pharmacist on 11/1. Started weekly emails every Monday to providers 
on 10/20. Final data collection tool administered 11/19. 
3. Study: Based on site champion and provider feedback a reminder must be placed in Epic. 
Site champion also stated that LMP and contraceptive use are not routinely documented 
at all female provider visits. The highest ratings on the final data collection tool were 
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placing a reminder in Epic and sharing TARCC with other primary care offices (4.3 and 
4.5 on 5-point scale, respectively). 83% stated they are very or extremely competent in 
using TARCC compared to 57% at the beginning of the project. 4.0 rating for the 
likelihood  of using TARCC in the next month compared to 3.7 at the beginning of the 
project. 
4. Act: Plan to work on developing a best practice advisory for Epic that flows into a 
decision tree with TARCC elements. Plan to work on developing triggers, questions, and 
prompts to give to providers for feedback over the next few months. After the project 
plan to pitch the idea to Duke Primary Care for possible inclusion in Epic. Also, the site 
champion has started reminding CMAs during huddle and using a whiteboard to ensure 
LMP and contraception are documented at each female visit regardless of chief 
complaint. LMP is now being done more often at female visits. Providers report looking 
at LMP more and documenting more (E. Stern, personal communication, November 20, 
2019). 
